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ABSTRACT 
 
ROLE OF BOVINE ILEAL SUB-EPITHELIAL MYOFIBROBLASTS AND 
EPITHELIAL CELLS IN INNATE IMMUNITY 
TIRTH UPRETY 
2018 
Gastro-intestinal (GI) tract harbors largest number of microbiota as well as the 
largest number of immune cells for a given tissue. The host needs to mount an effective 
immune response against invading pathogens and tolerance against commensals. Thus, 
regulatory mechanism and barrier function of the GI tract are of utmost importance for 
appropriate host microbe interaction and gut homeostasis. Intestinal epithelial cells 
(IECs) act as the first line of defense against invading pathogens. IECs recognize 
pathogens and commensals and mount an effective innate immune response. Such 
recognition of pathogens is mediated through germ line encoded pattern recognition 
receptors (PRRs). Intestinal sub-epithelial myofibroblasts (ISEMFs) reside just beneath 
the surface epithelium and are involved in maturation and differentiation of epithelium. 
ISEMFs protect from pathogens that breach surface epithelium by expressing PRRs. Lack 
of stable intestinal epithelial and sub-epithelial myofibroblast cell lines has slowed down 
scientific studies on these cells. In this study, we established and characterized ISEMF 
cells from the ileum of a 2-day old calf. We also had generated stable bovine ileal 
epithelial cell (BIEC-c4) cultures in our lab. On real time-quantitative polymerase chain 
reaction (RT-qPCR) analysis both these cell types expressed Toll-like receptors (TLRs) 
1-9. To investigate their responses to various pathogen-associated molecular patterns 
xviii 
 
(PAMPs), we stimulated both cell types for 3 hours and 24 hours with various PAMPs. 
The RT-qPCR assay was used to investigate changes in TLR gene expression and in 
cytokine genes following stimulation. Lipopolysaccharide, peptidoglycan, and flagellin 
were used as bacterial ligands of surface PRRs. Similarly, γ-D-Glu-mDAP, muramyl 
dipeptide, polyinosonic:polycytidylic acid, poly I:C complexed with lyovec, and 
imiquimod were used as ligands of cytosolic and endosomal PRRs. Bovine ileal ISEMFs 
responded to bacterial PAMPs and to ligands of cytosolic and endosomal PRRs by 
significantly altering TLR gene expression. Unlike bovine ISEMFs, BIEC-c4 cells 
responded only to bacterial ligands. Thus, we conclude that bovine ileal ISEMF can be a 
good model to study innate immune responses and signaling pathways occurring at sub-
epithelial compartment. However, BIEC-c4 cells may serve as a good in-vitro model to 
study enteric infectious disease pathogenesis and innate immune responses associated 
with them. 
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Chapter 1. Introduction and Objectives 
1.1 Introduction 
Humans and animals being constantly exposed to myriad pathogens, within and 
outside of the body, need a robust system that can rapidly respond to invading pathogens. 
The immune system has evolved with evolving pathogens into an intricate system where 
it is difficult to compartmentalize it into sub-systems. In general, the immune system can 
be broadly classified into innate immunity and adaptive immunity.  
Innate immunity comprises of anatomical barriers and germ line encoded 
receptors that recognize molecular patterns conserved across microorganisms and 
pathogens whereas adaptive or acquired immunity relies mainly on T-cell and B-cell 
responses against pathogens. Traditionally, innate immunity was characterized as non-
specific immunity, but a recent understanding of innate immune system has shown the 
specificity in recognizing a virus or bacteria or intracellular and extracellular pathogens. 
Innate immunity’s ability to recognize danger associated molecular patterns (DAMPs) 
that arise after necrotic cell death restricts the extensive cellular damage. Moreover, to 
mount a strong adaptive immune response requires stimulatory signaling from the innate 
immune system. Innate immunity’s rapid response to invading pathogens precedes that of 
adaptive immunity and thus is important in limiting initial invasion by pathogens. Recent 
understanding of the significance of innate immunity has led to a renaissance of 
researches aimed at the better understanding the molecular mechanism of innate immune 
responses. 
One of the various methods of pathogen recognition by the innate immune system 
is through recognition of pathogen associated molecular pattern (PAMPs) and the 
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recognizing receptors are pattern recognition receptors (PRRs). Toll-like receptors 
(TLRs) are transmembrane proteins that are part of PRR family and recognize conserved 
regions in bacteria, viruses, fungi or protozoa through leucine-rich repeat in their 
extracellular domain. Researchers are aiming at harnessing the potential therapeutic 
application of TLR signaling, especially in vaccine synthesis where TLR agonist are used 
as adjuvants for eliciting a strong immune response. Such a novel approach includes 
vaccination strategies for influenza vaccine (1), Mycobacterium tuberculosis vaccine (2), 
cancer vaccine like human papilloma virus (HPV) (3). A better understanding of cellular 
responses to various TLR agonists will help in designing approaches to manipulate 
immune response for therapeutic purposes. These PRRs constantly interact with 
microorganisms and mount a pro-inflammatory or anti-inflammatory response, 
whichever deemed essential.   
Of various sites of host-microbe interaction, the gut epithelium is of utmost 
importance as it harbors trillions of commensals and pathobionts forming an ecological 
community called as gut microbiota. Intestinal epithelial cells have two major functions, 
segregation of gut microbiota and host intestine and mediate signals between microbiota 
and immune cells. Intestinal epithelial cells are constantly producing antimicrobial 
peptides, mucins, cytokines like IL-12, IL-27, IL-17 and chemokines to ward off 
pathobionts and pathogens (4). Constant production of pro-inflammatory cytokines by 
intestinal epithelial cells can lead to disease like Inflammatory Bowel Disease (IBD). 
Thus, intestinal epithelial cells need to balance the pro- and anti- inflammatory immune 
response. Just beneath the intestinal mucosa lies mesenchymal cells notably fibroblasts 
and myofibroblasts. These cells provide structural support as well as play vital role in 
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maturation and differentiation of epithelial cells (5) and in immune regulation at mucosal 
and sub mucosal levels (6). Many studies have focused to understand their role in innate 
immunity when the first line of defense is compromised. 
In vivo efforts to better understand the mechanisms by which intestinal epithelial 
cells maintain the harmony between pro and anti-inflammatory responses in response to 
constant interaction with gut microbiota is challenging. In vitro studies on intestinal 
epithelial cells enable to investigate mechanisms at cellular and molecular level. 
Researchers routinely use cell lines to study biological processes, however, unavailability 
of genotypically and phenotypically characterized bovine intestinal epithelial cell lines 
and intestinal sub-epithelial myofibroblast cell lines has made it difficult to study innate 
immune responses at intestinal mucosal and sub-mucosal level in bovine species. The 
development and characterization of a stable bovine intestinal sub-epithelial 
myofibroblast cell line will help us to investigate immune responses occurring beneath 
the mucosal level. The study proposed here will serve to understand the responses of 
intestinal epithelial cells and intestinal sub-epithelial myofibroblasts to various bacterial 
and viral ligands in terms of expression of TLRs,cytokines and chemokines. The research 
findings will help researchers in designing approaches to use TLR agonists for further 
immune system modulation and therapeutic strategies.  
1.2 Objectives 
The objectives of the study: 
1. To establish and characterize a stable bovine intestinal sub-epithelial 
myofibroblast (ISEMF) cell line from the ileum of the 2-day old calf.  
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2. To analyze and study the expression of Toll like receptors (TLRs) by ISEMFs and 
investigate their responses to pathogen associated molecular patterns (PAMPs).  
3. To analyze and study the expression of Toll like receptors (TLRs) by bovine 
intestinal epithelial cells line (BIEC-c4) and investigate its responses to pathogen 
associated molecular patterns (PAMPs). 
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Chapter 2. Review of literature 
2.1 An overview of the immune system 
Edward Jenner by vaccinating against small pox laid the foundation for research 
into the field of Immunology. Shibasaburo Kitasato and Emil von Behring led the 
foundation for passive immunization by using antitoxins against tetanus. This led Paul 
Ehrlich to propose side chain theory which later was considered as a mechanism of 
antibody production from B-cell. Elie Metchnikoff observed cells that could engulf 
bacteria and coined them as phagocytes. In doing so, he laid the foundation for studies on 
innate immunity (7). During the early phase, scientists debated on what protected the 
body from pathogens. Some argued for cells like phagocytes while other supported 
humoral components like the then antitoxins (antibodies). Early research in immunology 
was dominated by humoral immunology as it could explain many immunopathologies. 
Later dichotomies like delayed type hypersensitivity and allograft rejection led to an 
appreciation of cell-mediated immunity. 
The immune system has evolved considerably over the course of evolution. From 
toxic peptides and gene inactivating process to forestall pathogens employed by simplest 
eukaryotes to development of an arsenal of cells capable of detecting pathogens and 
mounting a specific response in higher vertebrates, it has developed into a complex 
system with no single definition to address this complexity (8). 
The immune system is an intricate network of immune and non-immune cells, 
tissues, and organs that protect the body from pathogens and harmful substances. Broadly 
the immune system can be classified into innate immunity and adaptive immunity and the 
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four major components of the immune system are barrier functions, immune tissues, 
immune cells, and protein/peptide defense (9). 
2.2 Components of innate immunity 
Innate immunity relies on germ line encoded receptors to mount an immune 
response against invading pathogens. Initially, it was considered as non-specific 
immunity. Research in the field of innate immunity has led to discoveries that show 
innate immunity to be specific. More than 90% of animal species rely solely on innate 
immunity for protection against pathogens (8).  
Anatomical and physiological barriers provide initial defense against pathogens. 
These barriers include skin, cilia, low pH of the intestine, and antimicrobial peptides. 
Innate immunity along with the barriers serves as the first line of defense. Traditionally 
innate immunity was described only as host component. Efflux of information from 
microbiome studies has shown that innate immunity is a result of complex interplay 
between host and microbes.  
Innate immunity relies on physical barriers, germ line encoded receptors, 
complement proteins, phagocytic cells, innate effector cells, and regulatory molecules 
like chemokines and cytokines (10). The absence of immunological memory separates 
innate immunity from adaptive immunity. Recent studies have shown a paradigm shift as 
innate immunity is shown to have some degree of immunological memory (11, 12). 
Innate immune cells like macrophages and natural killer cells (NK cells) upon 
reintroduction of similar infection show enhanced immunity. This enhanced immunity is 
independent of either B-cell or T-cell and is termed as ‘trained immunity’. This trained 
immunity could result from metabolic reprogramming of innate immune cells (13, 14). 
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Such immunological memory is also observed in copepods that lack an adaptive immune 
system and could possibly be a function of innate lectins (11). Trained immunity is also 
shown to exist in disease models of human neonates (15). 
2.2.1 Pattern Recognition Receptors (PRRs)  
In 1989 Charles Janeway Jr proposed the Pattern Recognition Receptor (PRR) 
theory. The central theme of this theory was that immune cells have receptors that 
recognize the microbial pattern and mount an effective immune response and provide 
necessary co-stimulation to an adaptive immune system for the further response (16). 
Such microbial patterns are conserved across the microbial groups and called as pathogen 
associated molecular patterns (PAMPs) or microbe associated molecular patterns 
(MAMPs).  There are 6 families of these PRRs (17): 
i. Toll-like receptors (TLRs) 
ii. C-type Lectins 
iii. Nod-like receptors (NLRs) 
iv. RIG-I like receptors (RLRs) 
v. AIM-2 like receptors (ALRs) 
vi. OAS-like receptors (OLRs) 
2.2.1.1 Toll like receptors (TLRs) 
Toll-proteins were initially identified in Drosophila as a transmembrane protein 
involved in the organization of dorso-ventral polarity of embryos (18). Later in 1996, 
researchers identified that Toll protein was involved in protection against fungal infection 
(19). A detailed history of discoveries in TLR study is enlisted in Fig 1 which is adapted 
from (20).  
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Fig 1: The history of Toll like receptors. Figure adapted from (20) 
TLRs are a type-I transmembrane glycoproteins with N-terminal ligand 
recognition domain, single transmembrane helix, and C-terminal cytoplasmic signaling 
domain. The cytoplasmic region has considerable homology to other receptors of 
Interleukin-1 receptors family (IL-1R) and thus signaling domains of TLR is called as 
Toll/Interleukin-1 receptor (TIR) domain. The transmembrane domain contains a stretch 
of nearly 20 hydrophobic residues. TLRs that sense nucleic acid PAMPs use the 
transmembrane domain to interact with nucleic acid PAMPs and directs these TLRs to 
endocytic compartments (21, 22). The ectodomain region of TLR is different from that of 
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IL-1R. TLR ectodomain contains leucine rich repeats which are stretch of 22-29 
hydrophobic residues in distinct interval involved in sensing of pathogens and the 
cytoplasmic region is involved in signal transduction (23, 24). Synthesis of TLR occurs 
in Endoplasmic Reticulum which is then trafficked to Golgi and ultimately recruited to 
the cell surface or to endosomes (25). Most mammals have ten TLRs (TLR 1-10) while a 
mouse has 13 TLRs (TLR 10 being a pseudogene) (26, 27). Sensing of PAMPs occurs 
through TLR ectodomain. PAMPs associated with various PRRs are listed in Table 1. 
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Table 1: TLR specific ligands. Adapted from (23). 
 
 
2.2.1.1.1 TLR signaling 
Sensing of PAMPs by TLRs leads to homo-dimerization or hetero-dimerization of 
TLR ectodomain. Dimerization of TLR ectodomains brings cytoplasmic domains near for 
dimerization and initiate downstream signaling (28-31). Dimerization of the cytoplasmic 
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domain is essential for the recruitment of signaling molecules. Downstream signaling 
molecules include adaptor protein called myeloid differentiation primary-response 
protein 88 (MyD88), IL-1R associated Kinases (IRAKs), transforming growth factor -β 
(TGF-β)-activated kinase (TAK1), TAB2, and tumor necrosis factor (TNF)-receptor 
associated factor 6 (TRAF6) (32, 33).  
2.2.1.1.1.1 MyD88 dependent signaling 
The MyD88 protein has a death domain (DD) at N-terminal and a cytoplasmic 
TIR domain. MyD-88 recruits IRAK to IL-1R complex by the interaction of DDs. It 
forms a homodimer of DD-DD and TIR domain-TIR domain when recruited to the 
receptor complex. It acts as an adaptor to recruit downstream signaling molecules that 
have DDs. MyD88 recruits IRAKs to form a complex called myddosome. Four different 
IRAK -like kinases have been identified (IRAK-1, IRAK-2, IRAK-4, IRAK-M). MyD88 
interacts with IRAK 4, IRAK 4 phosphorylates IRAK 1. Auto phosphorylated IRAK 1 
becomes fully functional. It then dissociates from the receptor complex. Fully functional 
IRAK 1 after dissociating from receptor complex activates ubiquitin E3 ligase TRAF 6 
which is an ubiquitin protein ligase. Ubiquitination of TRAF 6 recruits TAK/TAB and 
IKK complexes. TAK is major complex that activates mitogen activated protein kinases 
(MAPK) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) 
along with Janus kinase (JNK), extracellular signal regulated kinases (ERK), and p38 
pathway. TLR signaling mainly activates p65/p50 heterodimer of NF-κB family which 
leads to the production of pro-inflammatory cytokines, chemokines and co-stimulatory 
molecules (7, 23, 34-37). 
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2.2.1.1.1.2 MyD88 independent pathway/TRIF-dependent signaling pathway 
TRIF (TIR-domain-containing adapter-inducing interferon-β ) consists of N 
terminal domain, TRAF 6 binding motif, a TIR domain and RHIM domain (Receptor 
interacting protein (RIP) homotyping interaction motif). RIP homotypic motif is essential 
for association with RIP 1. RIP 1mediates NF-κB activation. Signaling through TRIF 
leads to activation of transcription factors like NF-κB, IRF3 (Interferon regulatory factor 
3), and activator protein 1 (AP 1). Phosphorylation activates C terminal regulatory 
domain of IRF3 which forms a dimer. After dimerization IRF3 is translocated to the 
nucleus. IRF 3 in nucleus recruits co-activators like p300 and CBP (cAMP-responsive-
element-binding protein (CREB)-binding protein. These co-activators activate 
transcription of type-I IFN. Type I IFN activates IFN inducible genes (7, 23, 37-42). 
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Fig 2: PRR signaling pathway along with regulator of signaling. Adapted from (43) 
2.2.1.1.2 Negative regulation of TLR signaling 
An excessive inflammatory cytokine produced during consistent TLR signaling 
may lead to endotoxic shock and systemic disorder. A negative regulation of TLR 
signaling occurs primarily through 3 major mechanisms. Dissociation of adaptor 
complexes, degradation of signal proteins, and transcriptional regulation all lead to 
negative regulation of TLR signaling. Molecules like suppressor of cytokine signaling 1 
(SOCS1), IRAK M, MyD88 short (MyD88s), single immunoglobulin IL-1R-related 
molecule (SIGIRR) negatively regulate TLR signaling. IRAK M prevents the formation 
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of IRAK1-TRAF complex by preventing dissociation of the MyD88-IRAK1-IRAK4 
complex. SOCS1 proteins belong to E3 ubiquitin ligase and promote degradation of 
TRAF proteins. MyD88s is a transcript variant of MyD88 and owing to its inability to 
bind to IRAK4, prevents NF-κB activation. Regulation of gene expression through 
transcription regulation is also employed in negatively regulating TLR induced gene 
expression. miRNAs have emerged as a regulator of TLR signaling. miR-155, a TLR 
induced miRNA can suppress and enhance TLR signaling. miRNAs have emerged as fine 
tuners of TLR signaling (23, 44-46). 
2.2.1.2 NLRs 
Nucleotide-binding oligomerization domain (NOD) like receptors (NLRs) are 
cytoplasmic proteins involved in recognition of intracellular bacteria. There are more 
than 22 identified members of the NLR family in humans and more than 30 in mice. Two 
most extensively studied NLR subgroup includes NLRC and NLRP.  NLRC are NOD 
proteins having N-terminal caspase recruitment domain (CARD), leucine rich repeats in 
C-terminus and nucleotide binding domain in between. In NLRP subgroup, CARD is 
substituted by Pyrin domain (47). NOD-1 and NOD-2 are two NOD proteins that 
recognize two different peptidoglycan fragments and are involved in pathogen 
recognition (48). Peptidoglycan (PGN) is a major constituent of gram-positive bacteria. 
In gram negative bacteria PGN is covered by a thick layer of lipopolysaccharide (LPS). 
PGN is composed of N-acetlyglucosamine (GlcNac) and N-acetylmuramic acid 
(MurNac) linked by β-(1-4) linkage (49). PGN’s role in producing an inflammatory 
response and stimulating immune response has been long known (50, 51). NOD-
1/CARD4 recognizes peptidoglycan GlcNAc-MurNAc-L-Ala-γ-D-Glu-meso-DAP (GM-
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TriDAP/iE-DAP) whereas NOD-2 recognizes muramyl dipeptide, MurNAc-L-AlaD-
isoGln. NOD-1 and NOD-2 activate NF-κB by recruitment of receptor-interacting serine/ 
threonine kinase (RICK) leading to secretion of pro-inflammatory cytokines while type I 
interferons are secreted when IRF3/IRF7 dependent pathway is activated by these 
receptors (52-56). NOD protein can function as a mediator of innate immunity itself and 
also a modifier of innate immunity resulting from TLR stimulation (57). 
2.2.1.3 RLRs 
Retinoic acid inducible gene (RIG) like receptors (RLRs) are family of RNA 
helicases. RLRs include RIG-I, melanoma differentiating gene 5 (MDA5) and recently 
identified LGP2 (laboratory of genetics and physiology 2) proteins. Intracellular dsRNA 
is sensed by RIG-I, MDA-5. RIG-I senses blunt ended 5’phosphorylated dsRNA whereas 
MDA-5 recognizes long (>1000 nucleotide) dsRNA (58-60). Both RIG-I and MDA-5 are 
RNA helicases that have caspase recruitment domain (CARD) and helicase domain. 
Signal transduction after sensing of intracellular dsRNA is through CARD in both RIG-I 
and MDA-5. This results in the activation of IRF-3 and NF-κB and subsequent 
production of IFNs (type I, type III) and as well as pro-inflammatory cytokines like IL-6 
and IL-8. LGP2 lacks CARD and is considered as a regulator of RIG-I and MDA-5 
mediated immune response (61-65). 
2.2.1.4 ALRs 
Absent in melanoma protein 2 (AIM-2) is a member of a protein family called as 
PYHIN (pyrin and HIN200 domain containing). AIM2 is associated with dsDNA (double 
stranded DNA) induced inflammasome activation and interleukin-1β (IL-1β) production. 
DNA in the cytoplasm either during viral replication or delivered by immune complexes 
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binds to AIM2. AIM 2 is an interferon inducible protein as it can bind to apoptosis 
related spec like protein (ASC) to form inflammasomes. Inflammasomes are multiprotein 
complex that can induce pyroptosis (caspase 1 dependent programmed cell death as 
means to combat intracellular pathogens by host cell) and pro-inflammatory cytokines 
like IL-1β (17, 66-69). 
2.2.1.5 OLRs 
2ʹ–5ʹ-oligoadenylate synthase (OAS) is a protein group that senses cytosolic 
dsRNA. Human OAS family consists of 4 IFN regulated genes OAS1, OAS2, OAS3, and 
OASL. OAS1, OAS 2, and OAS 3 can recognize cytosolic dsRNA and synthesize 2ʹ–5ʹ-
oligoadenylate synthase which in turn activates RNase L which binds and degrades viral 
RNA. There is limited understanding of the mechanism of sensing dsRNA by OAS and 
RNase L binding to dsRNA (70-72). 
2.2.1.6 C-type lectin receptors (CLRs) 
C-type lectin receptors (CLR) are transmembrane receptors that bind to 
carbohydrates through carbohydrate binding domains (CRD). CLRs also include a 
protein that does not recognize carbohydrate ligands but has structurally similar C-type 
lectin domains (CTLDs). CLR activation can directly or indirectly induce intracellular 
signaling. Lectins like dectin-2, macrophage-inducible C-type lectin (Mincle) indirectly 
induce signaling by associating with immunoreceptor tyrosine-based activation motif 
(ITAM) containing adaptor molecules. During direct induction of signaling CLRs like 
Dectin 1 have ITAM like motif in the cytoplasmic region of the protein which they 
employ to induce signaling. In both cases, phosphorylated spleen tyrosine kinases are 
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recruited. A series of signaling steps lead to activation of NF-κB, mitogen associated 
protein kinase (MAPK) which trigger cellular responses (73-75).  
2.3 Cytokines 
Cytokines are small non-structural proteins with molecular weight of 8-40,000 
dalton. It is a biological function rather than consensus structural motif or amino acid 
sequence that groups cytokines into a different class (76). Cytokine comprises of a range 
of molecules that transmit intercellular signals. In the immune system, these orchestrate 
immune function by involving in the generation of an inflammatory response and 
restraining the inflammation (77, 78). Broadly the two major groups of cytokines are type 
I and type II cytokines. Type I cytokines signal through type I cytokine receptor. Type I 
cytokine have four α helical bundle and are further grouped into the short chain and long 
chain. Type I short chain cytokines are 15 amino acids long while long chain cytokines 
are 25 amino acid long. The IL-2 family of cytokine is grouped as short chain type I 
cytokine. IFN (IFN-α/β/γ) and IL-10 are grouped as type II cytokines (77, 79, 80). Based 
on immune function cytokines can be classified as pro-inflammatory and anti-
inflammatory cytokines. 
2.3.1 Pro-inflammatory cytokines 
Predominantly secreted by activated macrophages, pro-inflammatory cytokines 
promote inflammation. These cytokines are also secreted by non-immune cells like 
fibroblasts, intestinal epithelial cells and endothelial cells (81).  
Interferons (IFN) are pro-inflammatory cytokines predominantly produced to 
combat viral infections. There are three types of IFN, type I, type II, and type III. Type I 
and type III are involved in antiviral response while type II is involved in regulation of 
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immune responses. Type I IFN binds to heterodimeric signaling complex composed of a 
single chain of IFNAR1 (IFN α/β receptor chain 1) and IFANR2 (IFN α/β receptor chain 
2). Heterodimeric receptor complex for type I and type III IFN is present in almost all 
nucleated cells. Type II IFN (IFN-γ) produced mainly by immune cells binds to the 
tetrameric receptor complex composed of 2 subunits of IFNGR1  (IFN γ receptor 1) and 
IFNGR2 (IFN γ receptor 2). Type I and type II IFN activate both common and distinct 
STAT (signal transducer and activator of transcription) (82, 83). 
Interleukin 1 was the first IL to be identified. Interleukin 1 (IL-1) family includes 
cytokines like IL-1α, IL-1β, IL-18, IL-33, IL-36 α, β, and γ. Cytokines belonging to IL-1 
family promote the activity of innate immune cells like neutrophils, eosinophils, natural 
killer (NK) cells. IL-1 is an endogenous pyrogen that acts on hypothalamus-pituitary-axis 
to induce fever. Elevated body temperature increases leukocyte migration. IL-1α 
mediates early phase of sterile inflammation and the IL-1α precursor is fully functional. 
Unlike IL-1α, IL-1β precursor requires caspase 1 cleaving to transform into active 
cytokine. IL-1β is usually produced by hematopoietic cells, tissue macrophages, and 
dendritic cells. IL-1α is produced by epithelial cells lining gut, lungs, liver etc. Although 
both IL-1α and IL-1β act by binding to IL-1R1 (Interleukin 1 receptor 1), differences in 
their function is due to the difference in the source of origin. IL-1α has an amino acid 
sequence called nuclear localization sequence (NLS) that allows IL-1α to localize in the 
nucleus and act as transcription component. IL-1β lacks NLS. IL-1 can activate 
macrophages and epithelial cells and produce acute phase response (84, 85).  
IL-6 is a pleiotropic cytokine and activates both T and B cells. It is mainly 
produced by macrophages and endothelial cells. IL-6 binds to membrane bound IL-6 
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receptor and associates with signaling glycoprotein gp130. Gp130 dimerization activates 
Janus kinase and ultimately leads to activation of MAP kinase. While limited number of 
cells express IL-6 R, an extensive number of cells express gp130. A soluble form of IL-
6R is generated into circulation to which IL-6 binds. This IL 6 bound receptor complex 
can activate gp130 thus increasing the IL-6 spectrum. Apart from acute phase response 
IL-6 promotes differentiation of naïve CD4+ T cells and thus links innate immune 
response with the adaptive immune system (T-helper cells) (86-88). 
Tumor necrosis factor-α (TNF-α) is produced as type II transmembrane protein 
which is cleaved by TNF- α converting enzyme (TACE). TNF exerts biological function 
by binding with membrane bound TNF receptor that has cysteine rich repeats in the 
cytoplasmic domain. Cytokine of the TNF family exerts a biological effect by activation 
of the NF-κB pathway (89). TNF-α is involved in the anti-tumor response, apoptosis, cell 
survival and induction of inflammatory response (90). TNF- α  is secreted by myeloid 
cells, antigen presenting cells, stromal cells, epithelial cells and activated T cells (91). 
IL-8 is a pro-inflammatory cytokine that belongs to CXC chemokine family. IL-8 
is neutrophil activating peptide and IL-8 acts as a chemoattractant for neutrophils, 
basophils and T cells. IL-8 acts through two receptors IL-8R A (CXCR1), and IL-8RB 
(CXCR2) (92, 93).  
2.3.2 Anti-inflammatory cytokines 
Anti-inflammatory cytokines are immune regulatory cytokines that check 
responses of pro-inflammatory cytokines. IL-1R antagonists, IL-4, IL-10, IL-11, IL-13 all 
act as anti-inflammatory cytokines (94).  
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IL-10 is an anti-inflammatory cytokine structurally related to IFN. Dysregulation 
of IL-10 leads to autoimmune disorders and immunopathies. Initially described as a 
cytokine produced from Th2 cells to check cytokine synthesis of Th1 cells, recent reports 
suggest that macrophages, dendritic cells also produce IL-10. IL-10 inhibits B7-1/B7-2 
expression on monocyte and macrophages. B7-1/B7-2 are co-stimulatory molecules that 
activate CD4+ T cells. IL-10 also inhibits secretion of pro-inflammatory cytokines and 
chemokines. IL-10 can thus limit T cell activation, inhibit production of pro-
inflammatory cytokines and affect Th1 and Th2 responses (95-97).  
2.4 Innate immune response at gastro-intestinal tract 
Gastro-intestinal (GI) tract harbors largest number of microbiota as well as the 
largest number of immune cells for a given tissue. Gut microbiota educates immune cells 
and is essential for the development of a robust immune system. The host, in turn, needs 
to mount an effective immune response against invading pathogens and tolerance against 
commensals and food antigens. Thus, regulatory mechanism and barrier function of the 
GI tract is of utmost importance for appropriate host microbe interaction and 
homeostasis. A key to achieving this dynamic interaction is to segregate host tissue from 
gut microbiota. Intestinal epithelial cells (IECs) maintain homeostasis by providing a 
physical barrier and by sensing and responding to microbial stimuli (98-100). 
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Fig 3: Schematic representation of the Intestinal Epithelial cell barrier. Adapted from 
(100). 
GI tract is divided into four layers; mucosa, submucosa, muscularis propria, and 
serosa. Mucosa is the innermost layer and consists of epithelium, lamina propria, and 
muscular mucosae. Muscularis propria consists of an inner circular muscle layer and the 
outer longitudinal muscle layer.  
The epithelium consists of different cell lineages originating from common stem 
cell progenitor. The epithelial layer is organized into crypts and villi. Pluripotent 
intestinal epithelial stem cells reside at crypts base. Enterocytes are most abundant cells 
in the intestinal epithelial layer and are involved in absorption of nutrients. Specialized 
secretory IECs are goblet cells that produce mucus, enteroendocrine cells that produce 
hormones, and Paneth cells that produce antimicrobial peptides like defensins. M cells 
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(microfold cells) lack villi and are involved in transcytosis of antigen and thus help in 
antigen sampling (101, 102). Recent reports suggest that M cells can uptake specific 
antigen by using surface glycoprotein receptor. Thus M cells are capable of both specific 
and non-specific antigen uptake from intestinal lumen (103). 
Mucin secreted from goblet cells acts as the first line of defense. Mucin deficient 
mouse develops colitis (104). Paneth cells are concentrated in the ileum and produce 
antimicrobial peptides like lysozymes, defensins, regenerating islet-derived protein-IIIγ 
(REGIIIγ). RegIIIγ is involved in host-microbial segregation in GI tract (105). Sensing of 
PAMPs by PRRs expressed in intestinal mucosa helps to mount an effective innate 
immune response against pathogens and induce tolerance to commensals. Such PRRs are 
expressed by intestinal epithelial cells and by mesenchymal cells like intestinal sub-
epithelial myofibroblasts (ISEMFs). Unlike other body sites, IECs in intestine express 
PRRs that are involved in altered responsiveness. PRRs in other body sites are associated 
with induction of inflammatory response upon sensing of PAMPs. In intestine where the 
majority of microbes are commensals, PRRs are involved in dampening of immune 
response and maintaining tissue homeostasis (106, 107). 
IECs express polymeric immunoglobulin receptor (pIgR). Secretory IgA (sIgA) 
produced by plasma cells binds to pIgR and this sIgA-pIgR complex is transcytosed to 
intestinal lumen. sIgA is essential to maintain intestinal homeostasis. Gut associated 
lymphoid tissue (GALT) and draining lymph nodes are essential for adaptive immune 
responses. These GALT are also part of the mucosal immune system. GALT consists of 
isolated lymphoid follicles or aggregated lymphoid follicles that collectively form 
Payer’s Patches. These sub-epithelial lymphoid aggregates reside in mucosa or 
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submucosa. Follicle associated epithelium lies above these lymphoid aggregates. One of 
the follicles associated epithelium is M cell. Sub-epithelial dome region is rich in 
dendritic cells and dendritic cell processes antigens after transcytosis by M cells. Solitary 
isolated lymphoid follicles (SILT) are microscopic lymphoid aggregates which can range 
from cryptopatches to isolated lymphoid follicles (ILF). NOD1 signaling in stromal cells 
promotes intestinal SILT maturation (99, 100, 108). 
Intestinal sub-epithelial myofibroblasts (ISEMFs) are mesenchymal cells residing 
beneath the intestinal mucosa (109-111). They also regulate the behavior of intestinal 
stem cells through intracellular mechanisms like Wnt, Bmp, Notch (5). ISEMF cells have 
been characterized as nonprofessional immune cells (112). They are also reported to be 
involved in the induction of peripheral tolerance in intestinal mucosa primarily through 
programmed death ligand-1 (PD-L1) mediated suppression of CD4+ T cell activity (113, 
114).   
GI tract is involved in both induction of immune response and maintenance of 
tolerance by identifying pathogens from commensals microbes. This complex task 
requires complex interplay between the mucosal barrier and immune cells. Intestinal 
epithelial cells and intestinal sub-epithelial myofibroblasts by expression of PRRs mount 
selective immune responses and are key players of intestinal innate immune responses. 
2.5 RT-qPCR 
Polymerase chain reaction (PCR) is a revolutionary concept developed by Karry 
Mullis in 1980. The enzyme DNA polymerase adds nucleotides (dideoxynucleotides; 
dnTPs) complementary to given template. Since DNA polymerase can add nucleotide 
only to 3’-OH group, it requires short nucleotide sequences called primer sequence. 
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Changes in temperature allow for control over polymerase activity and primer binding. 
Conventional PCR could only detect the presence of a specific gene. Conventional PCR 
could not infer relative abundance of a gene in two samples. To overcome this, 
fluorescence-based chemistry was developed called as real time-PCR or quantitative PCR 
(qPCR). qPCR can obtain amplification data in real time. If complementary DNA 
produced by reverse transcribing of mRNA is used as a template for PCR, it is called as 
reverse transcriptase PCR. Fluorescence based real time reverse transcriptase PCR allows 
for quantification of steady state mRNA expression. SYBR green based qPCR is one of 
the widely used fluorescence-based PCR assay. SYBR green dye is a fluorescent dye that 
binds to double stranded DNA only. Fluorescence occurs only if SYBR green dye is 
bound to double stranded DNA. As the amplification occurs, fluorescence increases as 
more double stranded DNA are being formed. A sensor collects all the data which is 
expressed in terms of Ct (threshold cycle) values. Ct value is the number of PCR cycles 
required by fluorescent signal to overcome background signal. A lower Ct value indicates 
stronger gene expression. Since SYBR green dye can bind to any dsDNA, the specificity 
of the data is validated using a dissociation curve or melting curve. A dissociation curve 
is obtained at end of PCR process by first denaturing all products followed by annealing 
and dissociation. The first derivative of the dissociation curve assesses the homogeneity 
of the PCR product. Two major quantification approaches are employed for qPCR data. 
For absolute quantification, a standard curve using serial dilution of known RNA 
concentration or copy number is plotted against Ct values. Ct value of the unknown 
sample for the gene of interest is used to assess concentration using standard curve. In 
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relative quantification, sample Ct values are normalized against the reference genes (115, 
116). 
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Chapter 3. Development and characterization of a stable bovine intestinal sub-
epithelial myofibroblast cell line from ileum of a young calf. 
 
Abstract 
Intestinal sub-epithelial myofibroblasts (ISEMFs) are mesenchymal cells that do 
not express cytokeratin but express α-smooth muscle actin and vimentin. Despite being 
cells with diverse functions there is a paucity of knowledge about their origin and 
functions primarily due to the absence of a stable cell line. Although myofibroblast in-
vitro models for humans, mouse, and pig are available, there is no ISEMF cell line 
available from young calves. We isolated and developed an ileal ISEMF cell line from a 
2-day old calf that expressed α-smooth muscle actin and vimentin but no cytokeratin 
indicating true myofibroblast cells. To overcome replicative senescence, we immortalized 
primary cells with SV40 large T antigen. We characterized and compared both primary 
and immortalized ileal ISEMF cells for surface glycan and Toll-like-receptors (TLRs) 
expression by lectin binding assay and real time-quantitative PCR (RT-qPCR) assay 
respectively. SV40 immortalization significantly decreased surface lectin binding for 
lectins GSL-I, PHA-L, ECL, Jacalin, Con-A, LCA, and LEL. Both cell types expressed 
TLR 1-9 and showed no significant differences in TLR expression. Thus, these cells can 
be useful in-vitro model to study ISEMF’s origin, physiology, and functions. 
 
Keywords: intestinal sub-epithelial myofibroblast, bovine, lectin, toll-like receptors. 
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3.1 Introduction 
Intestinal sub-epithelial myofibroblasts are mesenchymal cells residing beneath 
the intestinal mucosa (109-111). Originally described by Kaye et al in 1968 (117) and 
later termed as myofibroblasts by Majno et al in 1971 (118), these cells have gained 
widespread interest due to their diverse functions ranging from wound healing (119), 
promotion of tumor progression (120), to their role in inflammatory bowel disease (IBD) 
(121). ISEMFs are important in the regulation of barrier function of the intestinal 
mucosa. They play a pivotal role in the development of the mucosal layer as they are 
involved in morphogenesis and cytodifferentiation of the intestinal mucosa (109, 110). 
Epimorphin/syntaxin 2, a mesenchymal protein expressed by ISEMF cells promotes 
morphogenesis of villi (122) and ISEMFs are also involved in restitution and 
differentiation of the epithelium by secreting stem cell factors, growth factors like 
transforming growth factor- β3 (TGF-β3), and amphiregulin (123, 124). They also 
regulate the behavior of intestinal stem cells through intracellular mechanisms like Wnt, 
bone morphogentic protein (Bmp), and Notch signaling (5). ISEMF cells have been 
characterized as nonprofessional immune cells (112) and nonprofessional antigen 
presenting cells (125). They also express Toll like receptors (TLRs) but their response to 
pathogen associated molecular patterns (PAMPs) have not been elucidated (126).  
Myofibroblasts have characteristics intermediate between a fibroblast cell and a 
smooth muscle cell (111, 127). They are characterized mainly by the presence of alpha-
smooth muscle actin (α-SMA) (123, 128) along with vimentin and negative to weak 
staining for desmin (112, 120, 129). Myofibroblast cell morphology transitions from 
discoid or polygonal to elongated with an increase in cell passage (111). 
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Limited understanding of ISEMFs owing to un-availability of stable ISEMF cell 
line has impeded studies on this cell type. Only a single bovine ISEMF cell culture study 
has been reported till date (130) and most of the other cell lines are either from rat (131-
133), mouse (126, 134) or humans (5). In this study, we established and characterized a 
stable ileal ISEMF cell line from the 2-day old calf that demonstrates characteristics 
peculiar to myofibroblast cells. 
3.2 Materials and Methods 
3.2.1 Establishment of primary ileal ISEMF cell culture 
An animal protocol for the use of a calf for cell line development was approved 
by SDSU Institutional Animal Care and Use Committee (IACUC). Ileum from 2-day old, 
colostrum deprived Holstein male calf, was collected in supplemented Hanks Balanced 
Salt Solution (HBSS containing 1% streptomycin-penicillin, 5ug/ml of gentamycin, 2 
mM of L-glutamine). The lumen was washed two times with warm phosphate buffered 
saline (PBS). Both ends of the ileal loop were ligated with silk suture after flushing the 
lumen with supplemented HBSS (HBSS-S). Lumen was filled with phosphate buffered 
saline (PBS) containing 1 mM dithiothreitol and incubated for 5-10 minutes in a water 
bath at 370 C with constant shaking to remove mucus. To digest the intestinal tissue, 
loops were filled with warm (370 C) HBSS-S containing 300 units/ml of collagenase-type 
II (catalog number LS004176, Worthington Biochemical 130 Corporation, NJ, USA) and 
0.24 units/ml of dispase (catalog number  50-100- 131 3345, Roche Diagnostics, IN, 
USA), and incubated at 370 C in water bath with constant shaking for 15 minutes. The 
contents were discarded and the process of digestion with collagenase and dispase was 
repeated, but incubation time was increased from 15 minutes to 45 minutes. The content 
29 
 
 
 
thus obtained were also discarded. The predigested epithelium and sub-epithelium were 
scraped with sterile scalpel blade after longitudinally opening the ileal loop. The contents 
thus obtained were incubated in HBSS containing 2.4 U/ml of dispase for 10 minutes and 
then centrifuged at 140 g for 3 minutes. The pellet was resuspended in 30 ml of DMEM 
(Dulbecco’s modified eagle media) containing 2% sorbitol and centrifuged at 50 g for 3 
minutes. The supernatant was collected and grown in T-75 flask containing DMEM-10 
media. DMEM-10 media contained DMEM, 10 % fetal calf serum, 1 % non-essential 
amino acids, and 1 % penicillin-streptomycin. The cells attached and started showing 
myofibroblast like morphology and retained myofibroblast like morphology even at later 
passages when observed under Olympus IX70 phase contrast microscope.  
3.2.2 Generation of SV40 immortalized ISEMF cell line. 
Passage 20, 0.5 X 106 ISEMF cells were seeded into 3 wells of a 6-well tissue 
culture plate. Cells in the first well were kept as such. Cells on the second well were used 
for negative control, and cells in the third well were used for transfection with pSV3-neo 
plasmid (ATCC® 37150) vector containing SV40 Large T Antigen gene. For 
transfection, Lipofectamine® 2000 (catalog number 11668-027, Invitrogen, Carlsbad, 
CA) reagent and manufacturer’s protocol were used.  The lipofectamine-plasmid 
complex was added on to cells in the third well whereas only lipofectamine was added in 
cells on the second well. All three wells were incubated with serum-free OPTI-MEM® 
media for 12 hours followed by washing with 1X PBS. Cells were then grown in 
selection antibiotic G418 (catalog number 10131-035, Thermo Fisher, Waltham, MA, 
USA) for 7 days at a concentration of 2500 µg/ml of media. After antibiotic selection 
cells were grown on fibroblast media containing 500 µg/ml of G418 antibiotic. 
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3.2.3 Immunocytochemical (ICC) staining of primary and SV40 immortalized 
ISEMF cells 
Monoclonal antibodies (mAbs) specific against epithelial, fibroblast, and smooth 
muscle cell markers were used to stain primary and SV40 immortalized cells using the 
protocol as described previously (135, 136). Briefly, cells cultured in T-25 or T-75 flasks 
were trypsinized using 0.05% of Trypsin EDTA (Corning®, reference number 25-052-
CV) and counted using hemocytometer to prepare 106 cells/ml suspension of primary 
ileal ISEMFs and SV40 immortalized ileal ISEMFs. Hundred microliter of cell 
suspension was used to prepare cytospins using a cytofuge (Cytospin 3; Thermo Shandon 
Inc. Pittsburgh, PA, USA). After air drying for 2 hours, the cytospins were fixed in 
acetone for 7 minutes. Slides were then washed with 1% PBS. Endogenous peroxidase 
was blocked by 7 minutes incubation of slides in blocking solution (0.3% hydrogen 
peroxide and 0.01% Sodium azide in PBS). To prevent further non-specific antibody 
binding, if any, slides were incubated with 1% goat serum for 20 minutes. An avidin-
biotin blocking kit (catalog number SP2001, Vector Laboratories, Burlingame, CA, USA) 
was used to block endogenous biotin. Specific mAbs were used to detect the presence of 
cytokeratin, α-smooth muscle actin (α-SMA), desmin and vimentin proteins by 
immunocytochemistry. Anti-cytokeratin mAb (mAb) C6909 (IgG2a isotype), anti-
vimentin mAb V5255 (IgM isotype), anti-alpha smooth muscle actin mAb A2547 
(IgG2a) and anti-desmin mAb D1033 (IgG1) were used. Isotype-matched controls, mAbs 
M9269 (IgG1 isotype), M9144 (IgG2a isotype) and 196 M5170 (IgM isotype) were also 
used. Cells incubated with PBS alone served as negative control. All primary and isotype 
control mAbs were bought from Sigma-Aldrich (Sigma-Aldrich, St. Louis-MO). Slides 
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were incubated for an hour with 100 µl (1 µg/ml) of the specific primary antibody or 
isotype controls. Slides were then washed and incubated with 100 µl (1:2000 dilution) of 
isotype-specific, biotinylated goat-anti mouse IgG2a, IgG1, and IgM antisera (Caltag 
Laboratories) for 30 minutes. Presence of specific protein in the ISEMFs was detected by 
incubating slides with the HRP-streptavidin solution for 30 min, followed by ready-to-use 
(RTU) diaminobenzene (DAB) substrate (Vector Laboratories, Burlingame, CA, USA). 
Hematoxylin was used as a nuclear stain. Images were taken with an Olympus BX53 
upright microscope at 20X magnification.   
3.2.4 Confirmation of SV40 immortalization by PCR 
Genomic DNA from the primary (passage 22) and SV40 immortalized ISEMF 
cells (passage 22) was extracted using DNeasy Blood & Tissue Kit (Catalogue number 
69504, Qiagen, Valencia, CA, USA). DNA concentration was quantified using Nanodrop 
2000 (Thermo scientific). Hundred nanograms each of genomic DNA extracted from 
primary ISEMFs, SV40 immortalized ISEMFs, and pSV3-neo plasmid containing SV40 
Large T Antigen gene were used to amplify SV40 gene using gene specific primers 
(Table 2) previously used by others (137). To amplify the gene of interest, we amplified 
the genomic DNA and pure plasmid using PCR. Taq PCR kit (catalog number E5000S, 
New England Biolabs, Ipswich, MA, USA) was used for PCR assay. The thermal profile 
used for PCR was; initial denaturation at 950C for 5 minutes, followed by 30 cycles of 
annealing and extension at 950C for 30 seconds, 550C for 60 seconds, 720C for 60 
seconds, and the final extension at 720C for 10 minutes. The amplicons were resolved in 
2% agarose gel by running it at 85 volts for 45 minutes. 
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Table 2: Primer Sequences used for amplification of SV40 gene in ISEMF cells 
Gene Primer sequence Product 
size (bp) 
Tm 
(0C) 
SV40 Forward: 
5′-AGCAGACACTCTATGCCTGTGTGGAGTAAG-3′ 
Reverse:  
5′-GACTTTGGAGGCTTCTGGATGCAACTGAG-3′ 
751 55  
 
3.2.5 Confirmation of SV40 immortalization by indirect immunofluorescence assay 
Indirect immunofluorescence assay was also performed to further confirm the 
presence of SV40 protein in immortalized cells. Twenty-five thousand primary ISEMFs 
(passage 17) and SV40 immortalized ISEMF cells (passage 38, 18 passage after 
immortalization) were cultured in the chambered slide. For each cell type, two chambers 
were used, the first chamber for isotype control and second for confirmation of 
immortalization. After 24 hours, the cells in the slide were washed with 1X PBS, fixed 
and permeabilized using acetone and methanol mix (1:1, 250 µL/chamber) and incubated 
at -200C for 10 minutes. Cells were washed again with PBS, blocked for non-specific 
protein binding by incubating for 20 minutes at room temperature after addition of 
blocking solution (1% goat serum in 0.2% Triton X and 1% PBS). Cells were washed 
again and 250 ul (4ug/ml concentration) of either mouse IgG2a isotype control (mAb 
M9144, Sigma, St. Louis, MO, USA) or mouse anti-SV40 specific monoclonal IgG2a 
antibody (Santa Cruz Biotechnology, Dallas, TX, USA; sc-53488) was added on 
respective chambers. Cells were then incubated at 370C for an hour. After washing with 
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PBS, Alexa Fluor 488 conjugated goat anti-mouse IgG secondary antibody (1:200 
dilutions, Invitrogen, USA, A-11001) was added and incubated in dark at 370C for an 
hour. Cells were washed with PBS, equilibrated by addition of 2X saline sodium citrate 
(SSC) buffer for 5 minutes followed by washing with PBS. Then, 250 µl of propidium 
iodide (1uM, 1:1,000 dilution) was added and incubated for 5 minutes for nuclear 
staining of cells. Cells were then washed and mounted using permaflour mounting 
reagent. Images were taken using an Olympus BX53 upright microscope at 20X 
magnification. 
3.2.6 Lectin Binding Assay:  
The binding profile of 23 different lectins (Table 3) was identified in both primary 
and SV40 immortalized ISEMFs as per manufacturer’s (Vector Laboratories, 
Burlingame, CA, USA) protocol. As per the protocol, cells were trypsinized and counted. 
Approximately 0.5X106 cells were transferred to 96-well U bottom plate. Cells were 
incubated for an hour at 40C with 100 µl of 10 µg/ml of specific biotinylated lectins. To 
show specificity of lectin binding, another well with the same number of cells was 
incubated with a same volume and concentration of lectin and its specific inhibitor 
solution. Cells were then washed three times with 1X PBS and centrifuged to pellet the 
cells. Cells were then incubated in dark with 5 µg/ml of streptavidin-FITC (1:200 
dilutions) at 40C for 30 minutes. Cells were then washed and resuspended in 200 µl of 
1% paraformaldehyde. For each assay, a separate well containing cells and streptavidin-
FITC was included as negative control. The percentage of cells staining with lectins was 
measured using FACS Calibur cytometer (Becton Dickinson, San Jose, CA, USA). 
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Primary ISEMF cells from passage 15-27 and SV40 immortalized ISEMF from passage 
40 (20 after immortalization)- passage 47 (27 after immortalization) were used. 
 
Table 3: Lectins and lectin inhibitors used for studying glycobiology of ISEMF cells 
Lectins Binding 
Specificity of 
Lectins 
Inhibitors Inhibitor 
concentration 
(mM) 
1. Glucose/Mannose 
group 
 
 
 
Canavalia ensiformis 
agglutinin (Con-A) 
α-Man,  
α-Glc 
α-methyl mannoside,  
α-methyl glucoside 
200 mM each 
Pisum Sativum 
agglutinin (PSA) 
α-Man,  
α-Glc 
α-methyl mannoside,  
α-methyl glucoside 
200 mM each 
Lens culinaris 
agglutinin (LCA) 
α-Man,  
α-Glc 
α-methyl mannoside,  
α-methyl glucoside 
200 mM each 
2. N-
acteylgalactasomine 
group 
   
Griffonia simplicifolia 
lectin I (GSL-1) 
α-GalNAc,  
    α-Gal 
Galactose 200 mM 
Soybean (Glycine 
maxi) agglutinin (SBA) 
α-GalNAc, N-acetylgalactosamine 100 mM 
Dolichohs biflorus 
agglutinin (DBA) 
α-GalNAc, N-acetylgalactosamine 100 mM 
Ricinus communis 
agglutinin (RCA-120) 
 β-GalNAc,  
    β -Gal 
Galactose 200 mM 
Sophora japonica 
agglutinin (SJA) 
β-GalNAc,  
 
N-acetylgalactosamine 100 mM 
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Vicia villosa agglutinin 
(VVA) 
β-GalNAc,  
 
N-acetylgalactosamine 100 mM 
3. N-
acetylglucosamine 
group 
   
Lycopersicon 
esculentum (tomato) 
lectin (LEL) 
β-GlcNAc Chitin hydrosylate 200 mM 
Solanum tuberosum 
(potato) lectin (STL) 
β-GlcNAc Chitin hydrosylate 200 mM 
Wheat (Triticum 
vulgaris) germ 
agglutinin (WGA) 
β-GlcNAc Chitin hydrosylate 200 mM 
Datura stramonium 
lectin (DSL) 
β-GlcNAc Chitin hydrosylate 200 mM 
Griffornia simplicifolia 
lectin II (GSL-2) 
α, β-GlcNAc Chitin hydrosylate 200 mM 
Succinylated WGA 
(SWGA) 
β-GlcNAc Chitin hydrosylate 200 mM 
Peanut (Arachis 
hypogaea) agglutinin 
(PNA) 
β -Gal Chitin hydrosylate 200 mM 
Erythrina cristagalli 
lectin (ECL) 
β -Gal,  
β-GalNAc 
Lactose 200 mM 
Artocarpus integrifolia 
(Jacalin) 
β -Gal Galactose 400 mM 
4. Fucose group    
Ulex europaeus 
agglutinin I (UEA-1) 
 
Α-Fuc No Inhibitor used  
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5. Oligosaccharide 
group 
   
Phaseolus vulgaris 
erythroagglutinin 
(PHA-E) 
Oligosaccharide No Inhibitor used  
Phaseolus vulgaris 
Leucoagglutinin (PHA-
L) 
Oligosaccharide No Inhibitor used  
6. Sialic acid group    
Sambucus nigra lectin 
(SNA) 
NeuAcα(2,6)Gal Lactose 200 mM 
Maackia amurensis 
lectin II (MAL-II) 
NeuAcα(2,3)Gal N-acetylneuraminic acid 
(NANA) 
200 mM 
 
3.2.7 Analysis of TLR expression in primary ISEMF and SV40 immortalized 
ISEMF by RT-qPCR 
For analysis of TLR expression by primary and SV40 immortalized ISEMF cells, 
we used SYBR-green based real time-quantitative polymerase chain reaction (RT-qPCR) 
assay. RNA was extracted from cells using RNeasy Mini Kit (catalog number 74101, 
Qiagen, Valencia, CA, USA). RNA was quantified using Thermo Scientific™ NanoDrop 
2000. One microgram of RNA was reverse transcribed to cDNA using TaqMan reverse 
transcription kit and kit protocol (TaqMan reverse transcription reagents, Applied 
Biosystems, catalog number N8080234). For RT-qPCR 2 µl of diluted cDNA (1:5 
dilution), 1 µl each of forward and reverse primer (10 µM stock), 10 µl of RT² SYBR® 
Green/ROX qPCR mastermix (catalog number 330501, Qiagen, Valencia, CA, USA) and 
6 µl of nuclease free water were added. The thermal profile used for amplification was: 2 
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minutes at 500C; 10 minutes at 950C; followed by 40 cycles of 45 seconds at 950C, 30 
seconds at 600C and 30 seconds at 720C. Ramping speed was set at 1.60C/second. 
QuantStudio™ 6 Flex Real-Time PCR System (Applied Biosystems, NJ, USA) was used. 
Data were normalized using the housekeeping gene (Cyclophillin-A). Primer sequences 
previously used (138) for amplification of TLR 1-9 gene and Cyclophillin-A as 
housekeeping gene (139) are listed in Table 4. Primary ISEMF cells from passage 15-20 
and SV40 immortalized cells from passage 33 (13 passage after immortalization) to 
passage 35 (15 passage after immortalization) were used for comparing TLR expression. 
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Table 4: Primer sequences of genes along with gene bank accession number used in 
analysis of TLRs expression of ISEMF cells  
 
 
Forward primer Reverse primer Accession 
number 
TLR 1 CAT TCC TAG CAG CTA 
CCA CAA GCT 
TGG GCC ATT CCA AAT 
AAG TTC T 
NM_001046
504 
TLR 2 GGG TGC TGT GTC ACC 
GTT TC 
GCC ACG CCC ACA TCA 
TCT 
NM_174197 
TLR 3 GGG CAC CTG GAG GTC 
CTT 
TTC CTG GCC TGT GAG 
TTC TTG 
NM_001008
664 
TLR 4 AGC ACC TAT GAT GCC 
TTT GTC A 
GTT CAT TCC GCA CCC 
AGT CT 
NM_174198 
TLR 5 GTC CCC AAC ACC ACC 
AAG AG 
GCG GTT GTG ACT GTC 
CTG ATA TAG 
NM_001040
501 
TLR 6 TTT ACC CTC AAC CAC 
GTG GAA 
GGG CCA AAG GAA CTG 
AAA AAC 
NM_001001
159 
TLR 7 CAC CAA CCT TAC CCT 
CAC CAT T 
GTC CAG CCG GTG AAA 
GGA 
NM_001033
761 
TLR 8 TGT GTT TAG AGG AAA 
GGG ATT GG 
TCT GCA TGA GGT TGT 
CGA TGA 
NM_001033
937 
TLR 9 CAG TGG CCA GGG 
TAG TTT CTG 
CCG GTT ATA GAA GTG 
ACG GTT GT 
NM_183081 
Cyclophilin-A CTTTCACAGAATAATTC
CGGGATT 
CAGTACCATTATGGCGTG
TGAAG 
BC105173 
 
3.2.8 Statistical Analysis: 
For comparison of differences in lectin binding between primary and SV40 
immortalized ISEMFs, two tailed two sample unequal variance t-test was used. A p-value 
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of less than 0.05 (p<0.05) was considered significant. For analysis of TLR expression in 
primary ISEMF, Ct values for TLR genes were normalized with housekeeping gene. The 
result was expressed as delta Ct (ΔCt). A lower ΔCt means stronger gene expression. A 
non-parametric test (Mann-Whitney U test) was used to compare normalized Ct (∆Ct) 
values (136). Mann-Whitney U test was applied using GraphPad Prism 7.04.  
3.3 Results 
3.3.1 Immunocytochemical (ICC) staining of primary and SV40 immortalized 
ISEMF cells 
The primary ileal ISEMF cells were cultured up to 27 passages without any 
changes in their morphological characteristics. SV40 immortalized ISEMF cells were 
passaged up to 20 passage after immortalization and were stocked after this passage. 
Cells obtained after scrapping of enzymatically digested ileal tissue in culture started 
showing stellate to spindle shape typical of myofibroblast cells (Fig 4). 
Immunocytochemical (ICC) characterization of primary ISEMF (Figure 5) and SV40 
immortalized ISEMF (Fig 6) cells showed positive staining for α-SMA (Fig 5C, and 6C) 
and vimentin (Fig 5B, and 6B), weak staining for desmin (Fig 5D, and 6D), and no 
staining for cytokeratin (Fig 5A and 6A).  A weak staining indicates few cells expressing 
the markers while negative staining indicates complete absence of staining. The 
specificity of staining was demonstrated by negatively stained isotype contol for each 
marker.  
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Fig 4: Phase contrast image of primary and SV40 immortalized ISEMF cells. A. Phase 
contrast image of primary ISEMF cells (cells obtained and cultured after scrapping of 
enzymatically digested ileal tissue). B. Phase contrast image of primary ISEMF cells 
(passage 1). C Phase contrast image of primary ISEMF cells (passage 15). D. Phase 
contrast image of SV40 immortalized ISEMF cells (passage 39, 19 passage after 
immortalization). Scale bar represents 100 µm for image A and 50 µm for rest of the 
images. 
 
41 
 
 
 
 
 
 
 
 
42 
 
 
 
Fig 5: Immunocytochemistry of primary ISEMF cells. Images on right are specific 
isotypes, and images on left are for cell specific markers. Brown pigmented cells indicate 
positive staining A. IgG2a isotype control, and anti-cytokeratin-IgG2a Ab staining. B. 
IgM isotype control, and anti-vimentin-IgM-Ab. C. IgG2a-isotype control, and anti-α-
SMA-IgG2a antibody. D. IgG1 isotype control, and anti-desmin- α-SMA-IgG2a 
antibody. Cells stained positive for α-SMA, and vimentin, weakly stained for desmin, and 
negative for cytokeratin. The scale bar at the bottom right of figure represents 50 µm 
length. Images are representative of 3 independent experiments. 
43 
 
 
 
 
 
 
44 
 
 
 
Fig 6: Immunocytochemistry of SV40 immortalized ISEMF cells. Images on right are 
specific isotype controls, and images on left are for cell specific markers. Brown 
pigmented cells indicate positive staining A. IgG2a isotype control, and anti-cytokeratin-
IgG2a Ab staining. B. IgM isotype control, and anti-vimentin-IgM-Ab. C. IgG2a-isotype 
control, and anti-α-SMA-IgG2a antibody. D. IgG1 isotype control, and anti-desmin- α-
SMA-IgG2a antibody. Cells stained positive for α-SMA, and vimentin, weakly stained 
for desmin, and negative for cytokeratin. The scale bar at the bottom right represents 50 
µm length. Images are representative of 3 independent experiments. 
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3.3.2 Generation of SV40 immortalized ISEMF cells and confirmation of 
immortalization  
After transfection of primary ISEMF cells with pSV3-neo plasmid, antibiotic 
selection with G418 resulted in SV40 immortalized ISEMF cells. To confirm the 
presence of the SV40 large T antigen gene, conventional PCR was performed, and 
product was resolved in 2 % agarose gel. Gel imaging confirmed the presence of the gene 
of interest in SV40 immortalized ISEMF cells (Fig 7), with  pSV3-neo plasmid and SV40 
immortalized ISEMF showing same amplified product size (751 bp) when amplified for 
SV40 large T antigen gene. Phase contrast microscopy showed SV40 immortalized 
ISEMFs cell resembled primary myofibroblasts in culture (Fig 4B). 
An indirect immunofluorescence assay confirmed the presence of SV40 large T 
antigen protein in SV40 immortalized cells (Fig 8L). Isotype control and primary cells 
did not show fluorescence when stained with Alexa fluor-488 conjugated anti-SV40 large 
T antigen-IgG2a antibody (Fig 8C, 8F, and 8I). 
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Fig 7: Gel image showing the presence of SV40 large T antigen gene in SV40 
immortalized ISEMF cells. Lane 1 shows 2 log DNA ladder. Lane 2 shows pSV3-neo 
plasmid. Lane 3 shows SV40 large T antigen gene in SV40 immortalized ISEMF cells. 
Lane 4 shows absence of SV40 gene in primary ISEMF cells. Lane 5 shows no template 
control. The size of the amplified product is 751bp. 
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Fig 8: Immunofluorescence assay to confirm the presence of SV40 large T antigen 
protein in SV40 immortalized ISEMF cells. A. Primary ISEMF cells with isotype control. 
B. Primary ISEMF cells nuclear staining C. Composite image of A and B. D. Primary 
ISEMF cells with SV40 specific mAb and Alexa 488 conjugated secondary antibody. E. 
Primary ISEMF cells nuclear staining. F. Composite image of D and E. G. SV40 
immortalized ISEMF cells isotype control. H. SV40 immortalized ISEMF cell nuclear 
staining I. Composite image of G and H. J. SV40 immortalized ISEMF cells with SV40 
specific mAb and Alexa 488 conjugated secondary antibody. K. Primary ISEMF cells 
nuclear staining. L. Composite image of J and K. Images are representative of three 
experiments. Scale bar at bottom right represents 50 µm.  
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3.3.3 Lectin Binding assay 
Out of 23 different lectins DBA, SJA, VVA, GSL-II, PSA, and UEA-I did not 
stain, or extremely low percentage of cells stained for these lectins in both cell types 
(primary and immortalized cells). Lectins RCA-120, LEL, GSL-I, STL, PHA-E, and 
PHA-L showed higher cell percentage of stained cells (>80%) in both cell types (Fig 9, 
and Fig 10). SV40 immortalization significantly decreased the percentage of cells 
staining for GSL-I ( 92.7± 1.17 for primary ISEMFs to 83.29± 2.07) for SV40 
immortalized ISEMFs), LEL (91.44±5.4 for primary ISEMFs to 73.7± 6.19 for SV40 
immortalized ISEMFs) and PHA-L (89.54±0.85 for primary ISEMFs to 72.02±5.82 for 
SV40 immortalized ISEMFs), Jacalin (62.18±11.72 for primary ISEMFs to 17.3±4.55 for 
SV40 immortalized ISEMFs), ECL (56.32±7.05 for primary ISEMFs to 18.09±5.4 for 
SV40 immortalized ISEMFs), Con-A (38.94±8.4 for primary ISEMFs to 4.65±2.4 for 
SV40 immortalized ISEMFs), and LCA (73.7±10.91 for primary ISEMFs to 24.34±8.2 
for SV40 immortalized ISEMFs) (Figure 11). Most of the inhibitors reduced the 
percentage of cell stained for specific lectins in both primary and SV40 immortalized 
cells (Figure 9 and 10). For SNA, the inhibitor reduced the percentage of stained cells, 
but it was not a complete inhibition.  
50 
 
 
 
S
B
A
D
B
A
S
JA
V
V
A
R
C
A
-1
2
0
G
S
L
-I
G
S
L
-I
I
D
S
L
L
E
L
S
T
L
W
G
A
S
W
G
A
P
N
A
Ja
ca
li
n
E
C
L
C
o
n
-A
P
S
A
L
C
A
U
E
A
-I
M
A
L
-I
I
S
N
A
P
H
A
-E
P
H
A
-L
0
20
40
60
80
100
Lectins
P
er
c
en
ta
g
e 
o
f 
ce
ll
s 
st
a
in
e
d
Lectins
Inhibitors
 
Fig 9: Lectin binding profile for primary ISEMF cells. Black bars show the percentage of 
cells staining for specific lectins and grey bars show inhibition of staining by specific 
inhibitors. Results are mean of three different experiments with error bars representing 
standard error of the mean (SEM). 
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Fig 10: Lectin binding profile for SV40 immortalized ISEMF cells. Black bars show the 
percentage of cells stained for specific lectins and grey bars show inhibition of staining 
by specific inhibitors. Results are mean of three different experiments with error bars 
representing standard error of the mean (SEM). 
 
52 
 
 
 
S
B
A
D
B
A
S
J
A
V
V
A
R
C
A
-1
2
0
G
S
L
-I
G
S
L
-I
I
D
S
L
L
E
L
S
T
L
W
G
A
S
W
G
A
P
N
A
J
a
ca
li
n
E
C
L
C
o
n
-A
P
S
A
L
C
A
U
E
A
-I
M
A
L
-I
I
S
N
A
P
H
A
-E
P
H
A
-L
0
20
40
60
80
100
Lectins
P
er
c
en
ta
g
e 
o
f 
ce
ll
s 
st
a
in
e
d
Primary ISEMF
SV40-ISEMF
*
*
*
* *
*
*
 
Fig 11: Comparison between primary and SV40 immortalized ISEMF for the percentage 
of cells stained for a given lectin. Significant differences in the percentage of cells stained 
for given lectin after immortalization are denoted by an asterisk (*). Results are mean of 
three different experiments with error bars representing standard error of the mean 
(SEM). 
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3.3.4 Analysis of TLR expression in primary ISEMF and SV40 immortalized 
ISEMF cells by RT-qPCR 
Normalized Ct values (∆Ct) for primary and SV40 immortalized ISEMFs were 
analyzed for any differences using Mann-Whitey U test. The test showed no significant 
differences in TLR expression after immortalization (Figure 12). The Ct values for 
housekeeping gene Cyclophillin-A ranged from 19.15-20.18 for primary ISEMF cells, 
and 22.09-22.39 for SV40 immortalized ISEMF cells. All 9 TLRs (TLR 1-9) were 
expressed by both primary and SV 40 immortalized ISEMF. TLR 2, 3, 4 had a relatively 
stronger expression (Figure 12) than other TLRs in both cell types. 
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Fig 12: TLR 1-9 expression in primary and SV40 immortalized ISEMF cells represented 
by normalized Ct values (normalized against the Ct values of housekeeping gene 
Cyclophillin-A). A lower ∆Ct indicates stronger gene expression. Mann-Whitney U test 
was applied to analyze the difference in ∆Ct between primary and SV40 immortalized 
ISEMF. P-value <0.05 was considered significant. The data are representative of three 
independent experiments. Error bar represents standard error of the mean (SEM). 
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3.4 Discussion  
ISEMF cells have diverse functions in wound healing, regulation of intestinal 
epithelial barrier function, maturation and differentiation of intestinal epithelium, 
orchestrating innate immune responses against invading pathogens, as well as role in the 
progression of tumors, and inflammatory bowel disease (119, 121, 123, 128, 140-144). 
Despite being cells with diverse functions, there is a paucity of knowledge about their 
origin (128) and function in fibrosis, inflammation, and repair of the intestinal mucosa 
(134, 145) primarily due to the absence of stable cell lines. Here, in this study, we 
successfully established and characterized a primary and SV40 immortalized ileal ISEMF 
cell lines from a 2-day old bovine male calf. 
After isolation of intestinal sub-epithelial cells, they were cultured in fibroblast 
supporting DMEM-10 media (134). These cells showed spindle to stellate morphology on 
culture. On immunocytochemistry, these cells stained positively for cell specific markers 
like α-SMA and vimentin but showed no staining for cytokeratin and weak staining for 
desmin. There is a consensus understanding regarding the presence of α-SMA, vimentin 
and absence of cytokeratin in intestinal myofibroblast cells (109, 110, 112, 127, 141). 
The presence of myofibroblast specific markers along with polygonal morphology 
confirmed the cells cultured in this study as ileal ISEMFs.  
 Intestinal myofibroblasts like other diploid cells undergo replicative senescence 
due to shortening of telomerase (146) and thus can be cultured only for a finite number of 
passages known as Hayflick’s limit (147). On reaching Hayflick’s limit they undergo 
senescence and stop dividing. Previously established bovine colonic 
myofibroblastsmaintainedtheir phenotype and proliferative capacity until passage 11 
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(130). However, in this study we were able to maintain primary ileal cells up to 27 
passages without losing proliferation and phenotypic characteristics. A possible 
explanation for this variation may be that unlike ileal myofibroblasts, colonic 
myofibroblasts need continuous stimulation with TGF-β to express myofibroblast marker 
α-SMA (148). The difference in age of animal (2-day old calf vs adult), site of cell 
isolation (ileum vs colon) and method of isolation could have resulted in this difference 
although further experiments need to be carried out to support these arguments. In two 
different studies, rat colonic myofibroblasts were successfully cultured up to 20 passages 
by Kawasaki et al (134) and only up to 9 passages by Pourreyron et al (149). One 
possible hypothesis for this discrepancy is that some cells can escape senescence 
spontaneously and acquire high proliferative capacity (134, 149).  
To immortalize primary ileal ISEMF cells, we transfected them with pSV3-neo 
plasmid containing (Simian Virus) SV40 large T antigen gene. Large T antigen produces 
tumor protein that binds with transformation related protein 53 (TRP53), Rb 
(retinoblastoma ) proteins pRb, p107 and p130 resulting in suppression of cell cycle 
arrest, and apoptosis (150). T antigen protein also binds to hsc70 causing the cell to enter 
S-phase of the cell cycle (151, 152). In this study, we confirmed the presence of SV40 
large T antigen gene in primary ileal ISEMFs by conventional PCR and confirmed the 
synthesis of SV40 large T antigen protein in cells by indirect immunofluorescence assay. 
SV40 immortalized ISEMFs retained myofibroblast morphology in culture and stained 
positive for α-SMA, vimentin, and negative for cytokeratin. Immortalization of primary 
cells by SV40 large T antigen has led to changes in expression of genes associated with 
immune function, antigen presentation, and metabolism in other transformed cells (153). 
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Therefore, we compared primary ISEMF cells and SV40 immortalized ISEMF in terms 
of changes in glycobiology and pattern recognition receptors (PRRs). 
We first compared primary and immortalized cells for the differences in their 
lectin binding profile. Lectins are proteins that bind to carbohydrates, glycolipids or 
glycoproteins in a reversible and non-catalytic manner (154, 155). Based on the type of 
glycans lectins bind, lectins can be classified into various groups such as N-
acetylglucosamine (GlcNAc), N-acetylgalactosamine (GalNAc), glucose, mannose, 
galactose, fucose, sialic-acid specific lectins (156). In immune system two main lectin 
groups are important; sialic-acid binding immunoglobulin like lectins (siglec) and C-type 
(calcium dependent) lectins. Among many functions, siglecs are associated with 
leukocyte adhesion and leukocyte homing. C-type lectins are involved in pathogen 
recognition (157). C-type lectin receptors in cells have crucial functions in infection 
regulation, autoimmunity, and cellular homeostasis (158). Pathogenic bacteria like 
Burkholderia can use fucose-binding lectins in host recognition (159). Protozoan like 
Entamoeba histolytica uses Gal-lectin for adherence to host cell glycans, Gal or GalNac 
(160, 161). Similarly, mannose-binding lectins activate complement pathways, enhance 
the immune response in concert with TLR 2/6, and bind to glycans on various pathogens 
(162, 163). Low levels of serum mannose-binding lectins predispose to the risk of 
Cryptosporidum infections in children (164). Lectins are also used as a cancer biomarkers 
for certain cancers (165). Lectin binding is routinely used to study specific soluble and 
cellular glycans and glycoconjugates expressed by specific cell types (166). Since all 
eukaryotic cells have glycans in the form of glycolipids, and glycoproteins, there is 
emerging evidence of their roles in cell signaling and cell adhesions.  
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Out of 23 different lectins used in this study, RCA-120, LEL, GSL-I, STL, PHA-
E, and PHA-L showed higher cell percentage of stained cells (>80%) in both cell types. 
Both primary and SV40 immortalized ileal ISEMF cells also stained fairly well for SNA, 
MAL-II, SBA, Con-A, PNA, ECL, Jacalin; however, they showed no staining to very 
faint staining for lectins UEA-I, SJA, VVA, GSL-II, DBA, PSA. SV40 immortalization 
decreased the percentage of stained cells for lectins LEL, PHA-L, GSL-I, Jacalin, ECL, 
Con-A, LCA, and PHA-L significantly. SV40 large T antigen mediated transformation of 
primary cells into immortalized cells is widely used and accepted method but it’s 
associated effects on cell physiology have not been widely studied (167). The 
immortalized cells can have altered phenotypes than primary cells due to changes in 
karyotype or due to loss of genes associated with phenotype (168, 169). There have been 
few studies on changes in glycosylation before and after immortalization of cells and they 
have shown altered glycosylation in transformed cell lines (170). There is increasing 
evidence that surface glycans are linked with tumor progression primarily by altering the 
glycosylation process (171-177). This could possibly be an explanation for variation in 
altered glycans after immortalization. Studies on differences in surface glycan expression 
by normal and tumor transformed cell line has shown a decrease in PHA-L binding in 
tumor transformed cell line (178). Another possible reason could be the differences in 
passage number. In this study, SV40 immortalized cells were of late passage, whereas 
primary cells were of early passage. Studies on skin fibroblast cells have shown decrease 
sialylation in aged individuals and in late passage fibroblast cells (179, 180). Further 
study to identify a possible explanation for altered surface glycans in SV40 immortalized 
ISEMFs is required to elucidate underlying mechanisms. The first step in the 
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pathogenesis of various bacterial and viral disease is interaction and binding of glycan-
binding protein (lectins) on specific surface receptors (surface glycans) on host cell (181-
184). Host cell uses these interactions to recognize pathogens and initiate an innate 
immune response (185, 186). Thus, identification of pathogen lectins and host glycan 
interactions could help in understanding disease pathogenesis (182). Expression of 
surface glycans from the sialic acid group by ISEMF cells represents a target for viral 
adhesions (187, 188). Various bacteria express adhesins. Some of the adhesins are 
expressed in the form of mannose-specific type-I fimbriae, and N-acetylglucosamine 
binding F-17 fimbriae (189). Expression of Mannose group glycans by ISEMF cells may 
indicate a possible target of adhesion with various bacteria. Thus, these cells can be a 
good model to study enteric bacterial and viral pathogenesis. 
Historically, the role of stromal cells was thought to be limited to only a structural 
function, but a plethora of evidence has emerged that shows vital role of these cells in 
innate immune responses (190). ISEMF cells in mouse, rat, and human models have 
shown their role in innate immunity (112, 125, 126, 191). To identify the expression of 
toll-like receptors (TLRs) by primary ISEMF cells, RT-qPCR based mRNA expression 
assay was used. Primary ISEMFs expressed TLRs 1-9 illustrating their role in innate 
immunity in the intestine. To compare changes in TLR gene expression, if any, upon 
immortalization with SV40 large T antigen, again RT-qPCR assay was used to compare 
normalized Ct values (∆Ct ) for TLRs 1-9 of primary and SV40 immortalized ISEMFs. 
Statistical analysis showed no significant differences in gene expression between the two 
cell types.  
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TLR is one of the groups in PRR family that recognizes pathogen associated 
molecular patterns (PAMPs). These PAMPs are highly conserved across pathogens. 
Recognition of PAMPs by TLRs results in production of pro-inflammatory and anti-
inflammatory cytokines by activation of MAPK/p38/JNK pathway, TAK1/NF-kB 
activation, and IRF3 or IRF7 pathways (17, 23, 43, 192). Breach in epithelial layer by 
invading pathogens may lead to activation of TLRs present in ISEMFs and consequently 
initiation of signaling pathways resulting in the release of cytokines and chemokines. 
Thus, ISEMFs are crucial in initiating an immune response against a pathogen that 
reaches sub-epithelial layers (193). In this study both primary and SV40 immortalized 
ISEMFs expressed various TLRs, another study needs to be carried out to evaluate the 
responses of ISEMFs to PRR ligands. 
3.5 Conclusion 
We were able to isolate, establish and characterize a bovine primary ileal ISEMF 
cell line. To delay replicative senescence, we immortalized this ISEMF cell line with 
SV40 large T antigen mediated transformation. Comparison of primary and SV40 
transformed ileal ISEMFs showed morphology and cell markers specific for sub-
epithelial myofibroblast cells. Study of cell surface glycan showed a decrease in lectin 
binding capacity for lectins GSL-I, PHA-L, LEL, Jacalin, ECL, Con-A, and LCA upon 
immortalization of ISEMFs. This decrease in lectin binding could be the result of SV40 
immortalization of primary ISEMFs or due to use of late passage cells for SV40 
immortalized ISEMF. We also analyzed expression of TLRs in both primary and SV40 
immortalized ISEMFs. Both cell type expressed TLR 1-9 and showed no significant 
differences in TLR gene expression. So far to the author’s knowledge, this is the first 
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instance of development of stable primary and immortalized bovine ileal ISEMF cell 
lines from a young calf. These cell lines could be used to study a wide range of 
physiological functions of ISEMFs and their role in disease pathogenesis. We intend to 
use these cells in further studies to investigate their role in innate immunity and 
pathogenesis of enteric diseases. 
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Chapter 4. Role of bovine intestinal sub-epithelial myofibroblasts in innate immune 
responses in the intestine 
 
Abstract 
Intestinal sub-epithelial myofibroblasts (ISEMFs) support the growth and 
differentiation of intestinal epithelium. Further, their role as a generator of immune 
responses in the sub-epithelial intestinal compartment is emerging. We have isolated, 
developed and characterized a stable bovine ileal ISEMF cell line that expresses 
myofibroblast markers including α-smooth muscle actin, and vimentin. Assessed by real 
time-quantitative PCR (RT-qPCR) analysis, these cells expressed Toll like receptors 
(TLRs) 1-9. In this study, we investigated their responses to various pattern recognition 
receptors (PRRs) bacterial and viral ligands. Primary ileal ISEMF cells were stimulated 
with PRR ligands for 3 hours or 24 hours. The RT-qPCR assay was employed to analyze 
TLR and cytokine gene expression and quantified as fold expression changes. At 3 hours, 
lipopolysaccharide (LPS) downregulated TLR 1, 4, 7, and 9 expression while 
peptidoglycan (PGN) downregulated TLR 6 and 8. Similarly, flagellin (FLA) 
downregulated TLR 4, 5, 7, 8, and 9 at 3 hours. At 24-hours LPS down regulated TLR 4 
and FLA downregulated TLR 6. At 3 hours, bacterial ligand γ-D-Glu-mDAP (iE-DAP) 
downregulated TLR 5 while muramyl dipeptide (MDP) and polyinosonic:polycytidylic 
acid (Poly I:C) downregulated TLR 1. Poly I:C complexed with lyovec  (Poly I:C/lyovec) 
downregulated TLR 3 after 3-hours stimulation. We also analyzed cytokines expression 
by RT-qPCR after stimulation with various bacterial and viral ligands. Interleukin 6 (IL-
6) was upregulated by LPS at 3 hours and 24 hours but downregulated by PGN at 24 
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hours. At 24-hours IL-1α was upregulated by PGN and Poly I:C/lyovec. TNF-α was 
downregulated by LPS at 24 hours while downregulated by FLA at 3 and 24 hours. 
Imiquimod upregulated TNF- α upon 24-hour stimulation. Anti-inflammatory cytokine 
IL-10 was downregulated by PGN upon 3-hour stimulation. As we observed changes in 
TLRs, pro-inflammatory and anti-inflammatory cytokine genes expression, we infered 
that bovine ISEMF cells responded to various bacterial and viral ligands. Thus, we 
conclude that bovine ileal ISEMF cells play a pivotal role in host defense against 
invading pathogens in the intestinal sub-epithelial compartment. 
 
Key-words: intestinal sub-epithelial myofibroblasts, innate immunity, bovine, TLRs, 
cytokines 
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4.1 Introduction 
Disruption of barrier function of intestinal epithelial cells exposes intestinal sub-
epithelial compartment to numerous pathogens and leads to enteric inflammatory diseases 
(194). The intestinal sub-epithelial compartment is populated with mesenchymal cells 
and the interaction of surface epithelium and mesenchymal cells are crucial in the 
maintenance of barrier function (195). Intestinal sub-epithelial myofibroblasts (ISEMFs) 
are α-smooth muscle actin and vimentin positive mesenchymal cells (109-111) pivotal in 
regulating barrier function, in fibrosis and healing, in differentiation, restitution, and 
morphogenesis of epithelium (5, 6, 109, 110, 122, 124, 144). Mounting effective immune 
response against invading pathogen in the intestinal sub-epithelial compartment is 
essential and recent studies have shown that ISEMFs may be crucial in orchestrating 
innate immune responses against invading pathogens (123, 128, 190).  
Toll like receptors (TLRs), a type of pattern recognition receptors (PRRs), are 
first to recognize and mount an effective innate immune response against invading 
pathogens (23, 196). Binding of pathogen associated ligands to TLRs induces MyD88 or 
TRIF dependent pathways leading to activation of NF-κB and MAPKs pathways and 
release of cytokine or chemokines (25). In murine and human models ISEMFs have been 
reported to express TLRs and respond to pathogen associated ligands by secreting 
cytokines and chemokines (19, 112, 126, 134, 193, 197). Pro-inflammatory cytokines are 
reported to be involved in cross-talk between intestinal epithelial cells and  ISEMF cells 
(195).  
Cytokines like IL-33 from intestinal sub-epithelial myofibroblasts stimulates 
intestinal stem cells and progenitor cells promoting differentiation of secretory intestinal 
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epithelial cells (198). Thus, the study of the pattern of cytokine and chemokine 
production from ISEMF cells in response to pathogen associated TLR ligands can open 
new avenues to treat enteric diseases. Although ISEMFs express TLRs and NOD-like 
receptors (NLRs) their elucidated response to various pathogen associated molecular 
patterns (PAMPs) is still lacking (6, 126). ISEMF cells are suggested to enhance acquired 
mucosal immune response as they have emerged as non-professional antigen presenting 
cells (112, 125, 199). They are also reported to be involved in the induction of peripheral 
tolerance in intestinal mucosa primarily through programmed death ligand-1 (PD-L1) 
mediated suppression of CD4+ T cell activity (113, 114). Thus, further studies to 
investigate the mechanism by which ISEMFs generate antagonistic responses is a must. 
This suggests emerging role of ISEMFs as focal immune cells in intestinal mucosal 
immunity. 
We previously established and characterized stable bovine ISEMF cells that 
express α-SMA and vimentin. On RT-qPCR assay ISEMF cells expressed TLRs 1-9. In 
this study we investigated the response of ISEMF cells to various PRR ligands and 
subsequent changes in the expression of pro- and anti- inflammatory cytokines and 
chemokines. 
4.2 Materials and Methods 
4.2.1 Cell lines and culture conditions 
Primary ISEMF cell line obtained from the ileum of the 2-day-old calf was used. 
Cells were grown in Dulbeco’s Modified Eagle Medium (DMEM)-GlutaMax™ 
(GIBCO) supplemented with 10 % fetal calf serum (FCS: Atlanta Biologicals, 
Lawrenceville, GA), pen-strep (100 IU/ml of penicillin and 100 ug/ml of streptomycin: 
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Invitrogen), and 1% of non-essential amino acids (HyClone 100X; GE Health Care Life 
Sciences). The supplemented media was named as myofibroblast media. In earlier study, 
on phase contrast microscopy, ISEMFs showed spindle shape typical of myofibroblasts 
morphology.  Immunocytochemistry showed the presence of α-SMA and vimentin 
confirming cells to be myofibroblasts. Moreover, the absence of cytokeratin indicated the 
absence of contamination with epithelial cells. Cells were grown in T75 flasks (75 cm2, 
Corning) in a humid chamber (370C, 5% CO2) until becoming confluent. Cells were 
detached and harvested using 0.05% Trypsin-EDTA (Corning; Manassas, VA). Half 
million cells were seeded into each well of six well tissue culture plate (Corning life 
sciences) for stimulating with PRR ligands. After 48 hours of incubation in a humid 
chamber, cells were washed three times with 1X phosphate buffered saline (PBS). Fresh 
media was added along with PRR ligands at a specific concentration in duplicates. A 
control was setup for each experiment. Each experiment was carried out in triplicates. 
4.2.2  PRR ligands for stimulation of ISEMF cells 
ISEMF cells were stimulated with PRR ligands for 3- and 24-hours using end-
time alignment method. Lipopolysaccharide (LPS: catalog number L6529-1mg) from 
Escherichia coli O55:B55 was used at 5 µg/ml concentration. Similarly, peptidoglycan 
(PGN: catalog number tlrl-pgnsa) from Staphylococcus aureus was used at 10 µg/ml and 
Flagellin (FLA: catalog number tlrl-stfla) from Salmonella typhimurium was used at 100 
ng/ml. We also stimulated cells for 3-hours and 24-hours using ligands of cytosolic and 
endosomal PRRs. γ-D-Glu-mDAP (iE-DAP: catalog number tlrl-dap) was used at10 
µg/ml, muramyl dipeptide (MDP: catalog number tlrl-mdp) at 10 µg/ml, 
polyinosonic:polycytidylic acid (Poly I:C: catalog number tlrl-pic) at 5 µg/ml, Poly I:C 
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complexed with lyovec (Poly I:C/lyovec: catalog number tlrl-piclv) at1 µg/ml, and 
imiquimod ( catalog number tlrl-imq) at 5 µg/ml. All the ligands were bought from 
Invivogen, CA, USA. For stimulating cells with bacterial ligands, primary ISEMF cells 
from passage 15-20 were used. For stimulating cells with cytosolic and endosomal PRR 
ligands, cells from passage 18-24 were used. 
4.2.3 RNA extraction and cDNA preparation 
After 3 hours or 24 hours of incubation with ligands, cells were washed three 
times with 1X PBS. Cells were then trypsinized using 0.05% Trypsin-EDTA and 
centrifuged to form a pellet. RNA was extracted from pelleted cells using RNeasy Mini 
Kit (catalog number 74101, Qiagen, Valencia, CA, USA) and kit protocol. RNA was 
quantified using Thermo Scientific™ NanoDrop 2000. The RNA thus obtained was used 
to prepare cDNA. 1 µg of RNA was reverse transcribed to cDNA using TaqMan reverse 
transcription kit and kit protocol (TaqMan reverse transcription reagents, Applied 
Biosystems, catalogue number N8080234).  
4.2.4 Real time-quantitative PCR (RT-qPCR) for quantifying gene expression 
For RT-qPCR 2 µl of diluted cDNA (1:5 dilutions), 1 µl each of forward and 
reverse primers, 10 µl of RT² SYBR® Green/ROX qPCR mastermix (catalog number 
330501, Qiagen, Valencia, CA, USA) and 6 µl of nuclease free water was added to bring 
total reaction volume to 20 µl. The thermal profile used for amplification was: 2 minutes 
at 500C; 10 minutes at 950C; followed by 40 cycles of 45 seconds (15 seconds for 
cytokine genes) at 950C, 30 seconds at 600C and 30 seconds at 720C. Ramping speed was 
set at 1.60C/second. QuantStudio™ 6 Flex Real-Time PCR System (Applied Biosystems, 
NJ, USA) was used. Data were normalized using the housekeeping gene (Cyclophillin-
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A). Primer sequence previously used (138) for amplification of TLR 1-9 gene and 
Cyclophillin-A as housekeeping gene (139) are listed in Table 5. RT-qPCR was also used 
to identify any changes in pro-inflammatory and anti-inflammatory cytokines, after 
stimulation with PRR ligands. List of cytokine and chemokine primers (138, 200) is 
provided in Table 6. 
   
Table 5: Primer sequence of genes along with gene bank accession number used in 
analysis of TLRs expression of ISEMF cells 
 
 
Forward primer Reverse primer Accession 
number 
TLR 1 CAT TCC TAG CAG CTA 
CCA CAA GCT 
TGG GCC ATT CCA AAT 
AAG TTC T 
NM_001046
504 
TLR 2 GGG TGC TGT GTC ACC 
GTT TC 
GCC ACG CCC ACA TCA 
TCT 
NM_174197 
TLR 3 GGG CAC CTG GAG GTC 
CTT 
TTC CTG GCC TGT GAG 
TTC TTG 
NM_001008
664 
TLR 4 AGC ACC TAT GAT GCC 
TTT GTC A 
GTT CAT TCC GCA CCC 
AGT CT 
NM_174198 
TLR 5 GTC CCC AAC ACC ACC 
AAG AG 
GCG GTT GTG ACT GTC 
CTG ATA TAG 
NM_001040
501 
TLR 6 TTT ACC CTC AAC CAC 
GTG GAA 
GGG CCA AAG GAA CTG 
AAA AAC 
NM_001001
159 
TLR 7 CAC CAA CCT TAC CCT 
CAC CAT T 
GTC CAG CCG GTG AAA 
GGA 
NM_001033
761 
TLR 8 TGT GTT TAG AGG AAA 
GGG ATT GG 
TCT GCA TGA GGT TGT 
CGA TGA 
NM_001033
937 
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TLR 9 CAG TGG CCA GGG 
TAG TTT CTG 
CCG GTT ATA GAA GTG 
ACG GTT GT 
NM_183081 
Cyclophilin-A CTTTCACAGAATAATTC
CGGGATT 
CAGTACCATTATGGCGTG
TGAAG 
BC105173 
 
Table 6: Primer sequence of genes along with gene bank accession number used in 
analysis of cytokine expression of ISEMF cells 
 
 
Forward primer Reverse primer Accession 
number 
IL-1α CAG TTG CCC ATC CAA 
AGT TGT T 
TGC CAT GTG CAC CAA 
TTT TT 
NM_174092 
IL-1β GAG CCT GTC ATC TTC 
GAA ACG 
GCA CGG GTG CGT CAC A NM_174093 
TNF-α CGC ATT GCA GTC TCC 
TAC CA 
GGG CTC TTG ATG GCA 
GAC A 
NM_173966 
IL-6 CCA CCC CAG GCA GAC 
TAC TTC 
CCA TGC GCT TAA TGA 
GAG CTT 
NM_173923 
IL-8 TGC TCT CTT GGC AGC 
TTT CC 
TCT TGA CAG AAC TGC 
AGC TTC AC 
NM_173925 
IL-10 AAGGTGAAGAGAGTCT
TCAGTGAGC 
TGCATCTTCGTTGTCATGT
AGG 
NM_174088 
 
 
4.2.5 Statistical analysis for interpretation of RT-qPCR data  
To compare the changes in TLR expression after ligand stimulation, double delta 
Ct (ΔΔCt) was calculated using the method previously described (201). Change in 
mRNA gene expression was calculated as 2-ΔΔCt. The method uses the following 
equation to calculate ΔΔCt: 
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ΔΔCt=∆Ct Treatment (Ct of reference gene Treatment-Ct Housekeeping gene 
Treatment)- ∆Ct Control (Ct of reference gene Control-Ct Housekeeping gene Control). 
A two tailed Student’s t-test was then used to compare fold expression changes 
after treatment with ligands. A p-value of less than 0.05 (p<0.05) was considered 
significant. GraphPad prism 7.04 was used to prepare graphs. Data are expressed as a 
mean ± standard error of the mean. 
4.3 Results 
4.3.1 Innate responses of ISEMF cells after 3-hours and 24-hours stimulation with 
bacterial ligands of surface PRRs  
LPS significantly downregulated TLR 1 (0.69±0.05, p=0.02), TLR 4 (0.52±0.08, 
p=0.03), TLR 7 (0.56±0.04, p=0.01), and TLR 9 (0.7±0.05, p=0.03) (Figure 13); 
however, PGN significantly downregulated TLR 6 (0.78±0.04, p=0.03), and TLR 8 
(0.64±0.08, p=0.04) (Figure 14) gene expression at 3-hour time point. FLA 
downregulated TLR 4 (0.6±0.08, p=0.04), TLR 5 (0.51±0.06, p=0.01), TLR 7 
(0.68±0.04, p=0.02), TLR 8 (0.55±0.06, p=0.02), and TLR 9 (0.6±0.01, p=0) (Figure 15) 
gene expression at 3-hour time point. Upon analysis of cytokine genes expressions, we 
found that LPS significantly upregulated IL-6 (7.63±0.89, p=0.02) (Figure 16), PGN 
downregulated TNF-α (0.56±0.05, p=0.01) and IL-10 (0.23±0.11, p=0.02) (Figure 17) 
while FLA only downregulated TNF-α (0.47±0.07, p=0.02) (Figure 18) gene expression 
at 3-hour time point. 
After 24-hour stimulation, LPS downregulated TLR 4 (0.75±0.06, p=0.04) 
(Figure 13) and FLA downregulated TLR 6 (0.77±0.02, p=0.01) (Figure 15) genes 
expressions while PGN had no significant differences in TLR expression (Figure 14). 
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Upon analysis of cytokine genes expressions at 24-hour time point, we found that LPS 
significantly upregulated IL-6 (3.6±0.28, p=0.01) and downregulated TNF-α (0.53±0.05, 
p=0.01) (Figure 16) genes. After 24-hour stimulation, PGN significantly upregulated IL-
1α (1.32±0.05, p=0.02) and downregulated IL-6 (0.94±0.01, p=0.02) (Figure 17) while 
FLA downregulated TNF-α (0.53±0.09, p=0.04) (Figure 18) genes expressions. 
Interestingly, no significant changes in the IL-8 gene expression were observed in 
response to LPS, PGN, and FLAs stimulation for 3 and 24 hours. 
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Fig 13: Fold changes in TLRs genes expressions in ISEMF cells upon stimulation with 
LPS. Data are expressed as a mean of 3 independent experiments and error bar represents 
standard error of the mean. A significant difference in gene expression after LPS 
treatment is denoted by an asterisk (*=p<0.05, **=p≤0.01). 
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Fig 14: Fold changes in TLRs genes expressions in ISEMF cells upon stimulation with 
PGN. Data are expressed as a mean of 3 independent experiments and error bar 
represents standard error of the mean. A significant difference in gene expression after 
PGN treatment is denoted by an asterisk (*=p<0.05, **=p≤0.01). 
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Fig 15: Fold changes in TLRs genes expressions in ISEMF cells upon stimulation with 
FLA. Data are expressed as a mean of 3 independent experiments and error bar represents 
standard error of the mean. A significant difference in gene expression after FLA 
treatment is denoted by an asterisk (*=p<0.05, **=p≤0.01). 
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Fig 16: Fold changes in cytokines genes expressions in ISEMF cells upon stimulation 
with LPS. Data are expressed as a mean of 3 independent experiments and error bar 
represents standard error of the mean. A significant difference in gene expression after 
LPS treatment is denoted by an asterisk (*=p<0.05, **=p≤0.01). 
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Fig 17: Fold changes in cytokines genes expressions in ISEMF cells upon stimulation 
with PGN. Data are expressed as a mean of 3 independent experiments and error bar 
represents standard error of the mean. A significant difference in gene expression after 
PGN treatment is denoted by an asterisk (*=p<0.05, **=p≤0.01). 
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Fig 18: Fold changes in cytokines genes expressions in ISEMF cells on stimulation with 
FLA. Data are expressed as a mean of 3 independent experiments and error bar represents 
standard error of the mean. A significant difference in gene expression after FLA 
treatment is denoted by an asterisk (*=p<0.05, **=p≤0.01). 
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4.3.2 Innate responses of ISEMF cells after 3-hour and 24-hour stimulation with 
ligands of cytoplasmic and endosomal PRRs 
After 3-hour stimulation, iE-DAP, a ligand for NOD-1 significantly 
downregulated TLR 5 (0.76±0.04, p=0.02) (Figure 19), MDP, a ligand for NOD-2 
downregulated TLR 1 (0.73±0.04, p=0.02) (Figure 20), Poly I:C, a ligand for TLR 3 
downregulated TLR 1 (0.74±0.03, p=0.01) (Figure 21), and Poly I:C/lyovec, a ligand for 
RIG-I and MDA-5 downregulated TLR 3 (0.49±0.05, p=0.01) gene expression. 
Imiquimod, a ligand for TLR 7 and 8 did not alter expression of any of the 9 TLRs 
(Figure 23). None of the ligands for cytosolic and endosomal PRRs, after 3-hour 
stimulation, significantly altered the expression of cytokines investigated in this study 
(Figure 24-28). We could not detect expression of cytokine IL-10 after 3-hour stimulation 
with ligand MDP indicating downregulation of IL-10 gene expression (Figure 25).  
Upon 24-hour stimulation, we observed no significant changes in TLR expression 
in response to any ligands of both cytosolic and endosomal PRRs (Figure 19-23). 
However, Poly I:C/lyovec significantly upregulated cytokine IL-1α (2.4±0.25, p=0.03) 
(Figure 27) and imiquimod significantly upregulated TNF-α cytokine gene expression  
(1.83±0.15, p=0.03) (Figure 28) after 24 hours of ligand stimulation. The expression of 
IL-10 gene remained undetected after both 3 hour and 24 hour stimulation indicating 
downregulation of IL-10 gene expression. 
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Fig 19: Fold changes in TLRs genes expressions in ISEMF cells upon stimulation with 
iE-DAP. Data are expressed as a mean of 3 independent experiments and error bar 
represents standard error of the mean. A significant difference in gene expression after 
iE-DAP treatment is denoted by an asterisk (*=p<0.05, **=p≤0.01). 
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Fig 20: Fold changes in TLRs genes expressions in ISEMF cells upon stimulation with 
MDP. Data are expressed as a mean of 3 independent experiments and error bar 
represents standard error of the mean. A significant difference in gene expression after 
MDP treatment is denoted by an asterisk (*=p<0.05, **=p≤0.01). 
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Fig 21: Fold changes in TLRs genes expressions in ISEMF cells upon stimulation with 
Poly (I:C). Data are expressed as a mean of 3 independent experiments and error bar 
represents standard error of the mean. A significant difference in gene expression after 
Poly (I:C) treatment is denoted by an asterisk (*=p<0.05, **=p≤0.01). 
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Fig 22: Fold changes in TLRs genes expressions in ISEMF cells upon stimulation with 
Poly (I:C)/Lyovec. Data are expressed as a mean of 3 independent experiments and error 
bar represents standard error of the mean. A significant difference in gene expression 
after Poly (I:C)/Lyovec treatment is denoted by an asterisk (*=p<0.05, **=p≤0.01). 
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Fig 23: Fold changes in TLRs genes expressions in ISEMF cells upon stimulation with 
imiquimod. Data are expressed as a mean of 3 independent experiments and error bar 
represents standard error of the mean. A significant difference in gene expression after 
imiquimod treatment is denoted by an asterisk (*=p<0.05, **=p≤0.01). 
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Fig 24: Fold changes in cytokines genes expressions in ISEMF cells upon stimulation 
with iE-DAP. Data are expressed as a mean of 3 independent experiments and error bar 
represents standard error of the mean. A significant difference in gene expression after 
iE-DAP treatment is denoted by an asterisk (*=p<0.05, **=p≤0.01). 
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Fig 25: Fold changes in cytokines genes expressions in ISEMF cells upon stimulation 
with MDP. Data are expressed as a mean of 3 independent experiments and error bar 
represents standard error of the mean. A significant difference in gene expression after 
MDP treatment is denoted by an asterisk (*=p<0.05, **=p≤0.01). 
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Fig 26: Fold changes in cytokines genes expressions in ISEMF cells upon stimulation 
with Poly (I:C). Data are expressed as a mean of 3 independent experiments and error bar 
represents standard error of the mean. A significant difference in gene expression after 
Poly (I:C) treatment is denoted by an asterisk (*=p<0.05, **=p≤0.01). 
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Fig 27: Fold change in cytokines genes expressions in ISEMF cells upon stimulation with 
Poly (I:C)/Lyovec. Data are expressed as a mean of 3 independent experiments and error 
bar represents standard error of the mean. A significant difference in gene expression 
after Poly (I:C)/Lyovec treatment is denoted by an asterisk (*=p<0.05, **=p≤0.01). 
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Fig 28: Fold changes in cytokines genes expressions in ISEMF cells upon stimulation 
with imiquimod. Data are expressed as a mean of 3 independent experiments and error 
bar represents standard error of the mean. A significant difference in gene expression 
after imiquimod treatment is denoted by an asterisk (*=p<0.05, **=p≤0.01).  
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4.4 Discussion 
In this study bovine ileal ISEMF cells expressed various TLRs and responded to 
various bacterial and viral ligands of PRRs by changing the expression of various pro-
inflammatory and anti-inflammatory cytokines (126). Inflammatory diseases of intestine 
or disruption of intestinal epithelium make sub-luminal compartment accessible to 
luminal antigens and pathogens to which ISEMFs respond by producing cytokines, 
chemokines, extracellular matrix components that modulate immune cells recruitment 
and activation (123, 202, 203). Cytokines and chemokines released in intestinal lumen or 
in the sub-epithelial compartment are key players in regulating barrier integrity (195, 
204). Understanding cell specific response and intracellular mechanism that generates 
innate immune responses against enteric pathogens are crucial for the development of 
prophylaxis against such pathogens (126). 
We first analyzed putative TLRs 1-9 expression in bovine ileal ISEMF cells. To 
identify if these cells respond to various pathogen associated molecular patterns and 
initiate any downstream signaling, we stimulated cells for either 3 hours or 24 hours with 
various ligands of PRRs. Stimulation for 3 hours mimicked early innate immune response 
while 24 hours mimicked late innate immune response. LPS significantly downregulated 
TLR 1, 4, 7, and 9 genes expressions after 3-hour stimulation and downregulated TLR 4 
after 24-hour stimulation. LPS upregulated IL-6 gene expression at both 3 hours and 24 
hours and downregulated TNF-α after 24-hour. The expression of TLR 4 to which LPS 
binds was downregulated by LPS stimulation (0.52 folds at 3 hours and 0.75 folds at 24 
hours) and coincided with decreasing trend of IL-6 expression (7.63 fold at 3 hours and 
3.6-fold at 24 hours) at 3 to 24 hours. LPS from gram negative bacteria is a potent 
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immunostimulatory structure. LPS consists of endotoxin Lipid A, core oligosaccharide, 
and O-antigen. Lipid A is recognized by TLR 4 (205, 206). LPS recognition by TLR 4 
requires accessory molecules. LPS binding protein binds to LPS allowing the association 
between LPS and co-receptor CD14 (monocyte differentiating antigen). CD-14 facilitates 
the binding of LPS to TLR 4/MD-2 complex (207, 208). Recognition of LPS by TLR 4 
leads to signal transduction either by MyD88 (209) or TRIF pathway (210) ultimately 
leading to activation of transcription factors like NF-κB, AP-1, and IRF-3. Activation of 
transcription factors results in expression of pro-inflammatory cytokines like IL-6, IL-8, 
TNF-α, and type -I IFN (20, 211). Previous studies have shown that LPS stimulates 
expression of IL-6 in hepatic myofibroblasts (212). Murine intestinal myofibroblasts also 
expressed TLR 4 and demonstrated elevated levels of IL-6 when measured at 8-hour post 
stimulation with LPS (126). Continued activation of TLR 4 can lead inflammation 
induced damages and thus negative regulation needs to be in place. Radioprotective 
protein 105 (RP105), single immunoglobulin IL-1R-related molecule, IL1-RL1 protein 
negatively regulate TLR 4 signaling. LPS challenged mice that are deficient for RP105 
showed elevated levels of TNF-α in serum (213). Thus, downregulation of TNF- α after 
24-hour stimulation with LPS in this study could probably be the result of negative 
signaling. After TLR signaling, the LPS-TLR4-MD2 complex is endocytosed in 
endosome or lysosomes where degradation of TLR 4 occurs (214). This degradation can 
result in the termination of TLR 4 induced production of TNF (215). In human colonic 
myofibroblasts LPS altered the expression of TLR 2, 3, 4, 6, 7 indicating that LPS could 
alter expression of other TLRs apart from its specific receptor TLR 4 (193) also observed 
in this present study.  
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Peptidoglycan (PGN) is a major constituent of gram positive bacteria cell wall 
and is composed of N-acetlyglucosamine (GlcNac) and N-acetylmuramic acid (MurNac) 
linked by β-(1-4) linkage (49). PGN’s role in inducing an inflammatory response and in 
stimulating innate immune responses has been long known (50, 51). TLR 2 knocked out 
mice revealed that TLR 2 is involved in recognition of PGN (216). In various cell 
models, PGN induced production of pro-inflammatory cytokines like IL-6, IL-1α/β, TNF-
α (217). In this study, TLR 6 and TLR 8 were significantly downregulated at 3 hours 
along with downregulation of TNF-α and IL-10. IL-1α was upregulated while IL-6 was 
marginally downregulated after 24 hours with PGN stimulation. Unlike LPS stimulation, 
PGN stimulation did not alter TLR 2 expression at 3-hour or 24-hour time point. In 
earlier studies stimulation of rat intestinal myofibroblast cultures with cell wall polymers 
altered expression of cytokines like IL-1β and IL-6 (218) and mice corneal fibroblast 
cultures also responded to PGN treatment by altering expression of TLRs other than TLR 
2 (219).  
TLR 1 and TLR 6 are functionally co-related with TLR 2 in recognizing different 
classes of lipopeptides (220). Most of the studies co-relating PGN to TLR 2 used 
commercially obtained PGN from Staphylococcus aureus. This preparation is often co-
purified with other cell wall components and pure PGN has failed to respond to TLR 2 in 
many experiments (221). The authors (221) even claimed that PGN sensing did not occur 
via TLR 2 which was later refuted (222).   
Flagellin (FLA), a subunit of flagellum protein provides motility to the bacterium. 
Flagellin initially was considered as a virulence factor but subsequent in-vitro studies 
demonstrated its pro-inflammatory role (223, 224). Later it was demonstrated that 
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recognition of flagellin by TLR 5 induced production of pro-inflammatory cytokines like 
TNF-α, IL-1β (225). In this study, 3- and 24-hours stimulation with flagellin 
downregulated TNF-α gene expression at both time points. TLR 4, 5, 7, 8, 9 genes 
expressions were downregulated at 3 hours while TLR 6 gene expression was 
downregulated at 24 hours. With three of these bacterial PRR ligands (LPS, PGN, and 
FLA) used in this study, we observed an alteration in expression of both cognate and non-
cognate receptors. Recent studies have shown cross talk among these PRRs and that PRR 
ligand can overexpress or inhibit expression of other PRRs. Among multiple ligands, LPS 
showed a more pronounced effect on modulating expression of other PRRs, and PAMPs 
other than LPS downregulated the expression of TLR 4 (226). Triggering of single TLR 
when the specific ligand is recognized is insufficient to mount an effective innate 
immune response and thus triggering of other PRR family or multiple TLR may be 
required to mount a strong immune response. Often the synergism is between PRRs that 
mediate effector response through different signaling pathways (43, 227).   
Nucleotide-binding oligomerization domain (NOD) proteins are cytoplasmic 
proteins involved in recognition of intracellular bacteria or their cell wall products. NOD 
proteins have N-terminal caspase recruitment domain (CARD), leucine rich repeats in C-
terminus and nucleotide binding domain in between. NOD-1 and NOD-2 are two NOD 
proteins that recognize two different peptidoglycan fragments and are involved in 
pathogen recognition (48). NOD-1/CARD4 recognizes peptidoglycan GlcNAc-MurNAc-
L-Ala-γ-D-Glu-meso-DAP (GM-TriDAP/iE-DAP) whereas NOD-2 recognizes muramyl 
dipeptide, MurNAc-L-AlaD-isoGln. NOD-1 and NOD-2 activate NF-κB by recruitment 
of receptor-interacting protein (RIP) 2 leading to secretion of pro-inflammatory cytokines 
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while type I interferons are secreted when IRF3/IRF7 dependent pathway is activated by 
these receptors (52-56). In this study, iE-DAP significantly downregulated TLR 5 while 
MDP downregulated TLR 1 gene expression after 3-hour stimulation with no changes in 
cytokine expression. MDP alone has been shown to evoke weak immune stimulation (47, 
228-231). However, addition of TLR agonists like LPS, lipoteichoic acid along with 
MDP has been shown to evoke a strong immune response (232, 233). TLR stimulation 
may promote internalization of MDP and iE-DAP which facilitates recognition by NOD 
proteins. NOD proteins also interact with other intracellular molecules such as GRIM-19, 
RIG-1, vimentin, RIPK2, NLRP1, that positively or negatively regulate NOD signaling 
pathways (47).  
During viral replication, most of the viruses produce double stranded RNA 
(dsRNA) as replication intermediate. This dsRNA is sensed by PRRs present in the cell 
membrane, cytosol, and endosomes. TLR 3 is membrane receptor usually present in 
endosomes and recognizes dsRNA. Retinoic acid-inducible gene I (RIG-I), melanoma 
differentiation-associated gene -5 (MDA-5), and NLR pyrin domain 3 (Nlrp3) are present 
in the cytosol and associated with sensing of dsRNA (62, 234-237). Recognition of 
dsRNA by these receptors results in the production of type -I interferon (IFN) (238, 239). 
TLR 3 uses MyD88 independent pathway and uses toll/interleukin-1 receptor (TIR) 
domain-containing adaptor inducing IFN-β (TRIF) ultimately leading to induction of 
IFN-β (210, 240, 241). Poly (I:C) is the synthetic analog of dsRNA and is used to mimic 
viral infection in experimental conditions (242, 243). Recent reports have shown possible 
role of CD14 in internalizing extracellular dsRNA or poly (I:C) and delivering to TLR 3 
located in the endosomal and lysosomal membrane (244). Apart from IFN, IL-6 induced 
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from TLR 3 expression is reported to have a detrimental effect during infection with 
single stranded RNA viruses (245-247). Apart from IFN production, NF-κB activation 
also induces secretion of IL-32. IL-32 induces production of pro-inflammatory cytokines 
like IL-6, IL-8, TNF-α, IL-1β (241, 248). With ISEMF cells in this study, we observed 
downregulation of TLR 1 gene expression at 3-hour stimulation with poly (I:C) however; 
we did not observe any significant changes in cytokines and TLR 3 expression.  
Poly (I:C) complexed with lyovec is Poly (I:C) complexed with a transfecting 
reagent that allows Poly (I:C) to be released into the cytoplasm. Accumulation of 
intracellular dsRNA during viral replication and subsequent induction of IFN production 
by the host cell is different from the IFN produced by sensing of extracellular dsRNA 
(249). Intracellular dsRNA is sensed by RIG-I, and MDA-5. Proteins RIG-I and MDA-5 
belong to RIG-I like receptor (RLR) family. RIG-I senses blunt ended 5’phosphorylated 
dsRNA whereas MDA-5 recognizes long (>1000 nucleotide) dsRNA (58-60). Both RIG-I 
and MDA-5 are RNA helicases that have caspase recruitment domain (CARD) and 
helicase domain. Signal transduction after sensing of intracellular dsRNA is through 
CARD in both RIG-I and MDA-5. This results in activation of IRF-3 and NF-κB and 
subsequent production of IFNs (type I, and type III) and as well as pro-inflammatory 
cytokines like IL-6 and IL-8 (61-64). However, poly (I:C) complexed with transfecting 
reagent lyovec in this study downregulated TLR 3 gene expression and significantly 
upregulated IL-1α  gene expression. 
Imiquimod is a synthetic guanosine analog with antiviral and anti-tumor activity 
(250). Imiquimod is an immune response modifier that specifically activates TLR 7 
signaling pathway (251). Through MyD88 signaling cascade imiquimod induces 
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activation of transcription factors like NF-κB and MAPKs (mitogen activated protein 
kinases). Activation of these transcription factors leads to induction of IFN-α, IL-12, 
TNF-α, IL-6 and other cytokines (250, 252-255). In this study, ileal ISEMF cells 
responded to imiquimod by upregulation of TNF-α gene expression after 24-hours 
stimulation but no changes in expression of TLR genes were observed. Immune cells like 
phagocytes produce reactive oxygen species (ROS) during the microbial invasion. These 
ROS are highly reactive and induce oxidative damage to nucleic acids, lipids, and 
proteins. Guanosine and cytosine are more prone to undergo oxidative damage due to 
their electronic configuration. Such damaged guanosine may be sensed by TLR 7 and 
TLR 8 and produce necessary cytokines for activating immune cells (251, 256).  
With most of the bacterial and viral ligands used in this study, we observed 
downregulation of TLRs. Some studies have suggested that TLR upregulation may favor 
entry of pathogens, especially in intestinal epithelium. In intestinal epithelium, TLRs 
upregulations is found to be associated with disruption of barrier function and thus may 
favor entry of pathogens (257). Thus, based on the findings of this study, intestinal 
myofibroblasts may also be involved in antiviral response and in activation of immune 
cells. 
4.5 Conclusion 
In this study, we investigated the putative expression of TLRs by bovine ileal 
ISEMF cells asthere has been a limited number of studies on the expression of PRRs by 
intestinal myofibroblast cells. To the author's knowledge, no studies on the role of bovine 
intestinal sub-epithelial myofibroblasts in innate immunity have been carried out so far. 
This study also analyzed the responses of bovine ISEMFs to various PAMPs and 
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associated cytokines expression. This study did not analyze expression of NLRs and 
RLRs in ileal ISEMFs. This study only analyzed changes in gene expression in response 
to various PAMPs. This study is limited in scope as it did not analyze whether alterations 
in mRNA expressions were being carried out to protein level. No experiment to quantify 
cytokine level in cell culture supernatant was performed and changes in IFN gene in 
response to viral PAMPs was not analyzed. Despite these limitations, we demonstrated 
that bovine ileal ISEMF express TLRs 1-9 and respond to various bacterial and viral 
PAMPs. Based on our experiments we can conclude that bovine ISEMFs are involved in 
generating an innate immune response in the intestinal sub-epithelial compartment. Thus, 
this cell line can be used to accumulate knowledge of signal transduction in response to 
various bacterial and viral PAMPs. This bovine ISEMF cell line can be an excellent in-
vitro model to study innate immune responses occurring at intestinal mesenchyma. 
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Chapter 5. Role of bovine ileal epithelial cells in innate immune responses in the 
intestine 
 
Abstract 
Intestinal epithelium plays important role not only in digestion but also in the 
maintenance of homeostasis in gastro-intestinal (GI) tract. It serves as a physical barrier 
in separating gut microbiota and lumen. There is a dynamic interaction among intestinal 
epithelial cells, intestinal mucosa and gut microbes. Knowledge of this interaction is 
essential for the better understanding of inflammatory and infectious enteric diseases 
where this delicate interaction is perturbed. Intestinal epithelial cells being equipped with 
pattern recognition receptors (PRRs) along with their proximity to gut microbiota play 
significant role in mounting innate immune responses to gut antigens and pathogens as 
well as in the maintenance of peripheral tolerance. We used cloned bovine-intestinal 
epithelial cell line (BIEC-c4) earlier developed from the ileum of the 2-day old calf to 
study putative expression of Toll like receptors (TLRs) and their responses to bacterial 
and viral pathogen associated molecular patterns (PAMPs). BIEC-c4 cells were 
stimulated with various PRR bacterial and viral ligands for 3 and 24 hours. The RT-
qPCR assay was employed to analyze TLRs and cytokines gene expression and 
quantified as fold expression changes. At 3 hours, we observed no changes in TLR 
expression after stimulation of BIEC-c4 cells with the lipopolysaccharide (LPS), 
peptidoglycan (PGN), and flagellin (FLA). At 24-hour peptidoglycan PGN upregulated 
expression of TLR 3 and 9. LPS upregulated interleukin 8 (IL-8) and IL-10 at 3 hours 
while IL-6 and IL-8 were upregulated at 24 hours. FLA downregulated IL-1β gene 
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expression at 3-hour after stimulation. Ligand γ-D-Glu-mDAP (iE-DAP) and muramyl 
dipeptide (MDP) upregulated TLR 9 expression at 3 and 24 hours after stimulation 
respectively. However polyinosonic:polycytidylic acid (Poly I:C) upregulated both TLR 
8 and TLR 9 expression after 3 hours of stimulation. Poly I:C complexed with lyovec  
(Poly I:C/lyovec) and imiquimod did not alter expression of any TLRs. Overall, findings 
of this study suggest that theBIEC-c4 cells serve as a good in-vitro model to study 
immune responses specifically against bacterial pathogens.  
 
Keywords: bovine intestinal epithelial cells, TLRs, cytokines, innate immunity  
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5.1 Introduction 
Intestinal epithelium is important in digestion and nutrients uptake. It is also 
involved in the maintenance of homeostasis in gastro-intestinal (GI) tract. It serves as a 
physical barrier in separating gut microbiota and luminal content from intestinal sub-
mucosa. The intestine is equipped with the largest arsenal of immune cells (204). 
Intestinal epithelial cells (IECs) play a significant role in inducing innate immune 
responses against invading pathogens. With both commensals and pathogens residing in 
the intestine, intestinal epithelial cells need to selectively mount an immune response 
against pathogens and develop tolerance against commensals. This dual task of 
maintaining tolerance as well as generating immune response surmounts unique 
challenge to the mucosal surface and specifically to intestinal epithelial cells (258). 
IECs secrete antimicrobial peptides like defensins and calprotectins that have 
broad-spectrum anti-bacterial activity (259-261). IECs express pattern recognition 
receptors (PRRs) that sense various pathogen associated molecular patterns (PAMPs). 
IECs being equipped with PRRs along with their proximity to gut microbiota have been 
shown to play role in mounting an innate immune response as well as in the maintenance 
of peripheral tolerance  (262-264). Toll like receptors (TLRs), a type of pattern 
recognition receptors (PRRs), are first to recognize and mount an effective innate 
immune response against invading pathogens (23, 196). Ten TLRs (TLR 1-10) have been 
reported in a bovine system with bovine intestinal epithelial cells expressing all ten of 
them (265-267). TLRs 1, 2, 4, 5, 6, 10 are expressed on the cell surface whereas TLR 3, 
7, 8, 9 are intracellular and located in endosomes. Cell surface TLRs sense protein, lipid 
and lipopolysaccharide PAMPs while intracellular TLRs sense nucleotide PAMPs (7, 25, 
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268). Binding of pathogen associated ligands to TLRs induces MyD88 or TRIF 
dependent pathways leading to activation of NF-κB and MAPKs pathways and release of 
cytokines or chemokines (25). Cytokines like IL-17, IL-10, IL-22, IL-36, IL-6 upregulate 
JAK-STAT pathway leading to increased expression of target genes essential for 
epithelial regeneration, proliferation, barrier integrity, activation of the adaptive immune 
system and pathogen clearance. (269-273).  
Development of stable intestinal epithelial cells that express PRRs and respond to 
PAMPs is pivotal in establishing an in-vitro model for studying enteric disease 
pathogenesis, signaling pathways and innate immune responses to pathogens. Cattles 
harbor enteric pathogens like enterotoxigenic Escherichia coli, Salmonella, 
Campylobacter, Mycobacterium, Listeria, Leptospira that cause huge economic losses to 
the livestock industry. Many of such zoonotic pathogens are equally important from a 
public health perspective (274-276). Development of host specific cell line helps in better 
understanding of disease pathogenesis and immune responses. There are limited number 
of stable primary cell lines available from the bovine intestine (265).  Most of the 
intestinal cell lines are either from adult cattle or from fetal tissues. Unavailability of 
intestinal epithelial cell lines from young calves have hindered studies on enteric 
pathogens like bovine rotavirus, bovine coronavirus, and bovine viral diarrhea virus that 
infect young calves (135, 277).  
Analysis of PRRs in the intestine, preferential activation of PRRs by pathogens, 
and cytokine signaling associated with PRR activation is essential for better 
understanding of gut immunity (264). In this study, we used an established and 
characterized cloned primary bovine intestinal cell line (BIEC-c4) from the ileum of the 
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2-day old calf which expressed TLR 1-9 as assessed by RT-qPCR assay. Here, we 
investigated the innate immune responses of BIEC-c4 cell line to various bacterial and 
viral PAMPs.  
5.2 Materials and Methods 
5.2.1 Cell lines and culture conditions 
Cloned primary bovine intestinal epithelial cells (BIEC-c4) obtained from the 
ileum of the 2-day-old calf were used in this study. BIEC-c4 cells were grown in 
DMEM/F12 (Dulbeco’s Modified Eagle Medium; GIBCO) media supplemented with 5% 
fetal calf serum (FCS: Atlanta Biologicals, Lawrenceville, GA), pen-strep (100 IU/ml of 
penicillin, 100 ug/ml of streptomycin: Invitrogen), 0.1% of mouse epidermal growth 
factor (EGF; Corning®, catalog number 4069007), and 0.1 % each of insulin, human 
transferrin and selenous acid (ITS; Corning®, catalog number 354351). The 
supplemented media was named as epithelial cell media. Cells were grown in T75 flasks 
(75 cm2, Corning) in a humid chamber (370C, 5% CO2) until becoming confluent. Cells 
were detached and harvested using 0.05% Trypsin-EDTA (Corning; Manassas, VA). Half 
million BIEC-c4 cells were seeded in each well of a six well tissue culture plate (Corning 
life sciences) for stimulating these cells with PRR ligands. After 48 hours of incubation 
in a humid chamber, cells were washed three times with 1X phosphate buffered saline 
(PBS). Fresh media was added along with PRR ligands at a specific concentration in 
duplicates. A negative control well was setup for each experiment. Each experiment was 
carried out in triplicates. 
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5.2.2 PRR ligands for stimulation of BIEC-c4 cells 
BIEC-c4 cells were stimulated with PRR ligands for 3 and 24 hours using end-
time alignment method. Lipopolysaccharide (LPS: catalog number L6529-1mg) from 
Escherichia coli O55:B55 was used at 5 µg/ml concentration. Similarly, peptidoglycan 
(PGN: catalog number tlrl-pgnsa) from Staphylococcus aureus was used at 10 µg/ml and 
Flagellin (FLA: catalog number tlrl-stfla) from Salmonella typhimurium was used at 100 
ng/ml. Cells from passage 55 -62 were used for stimulating BIEC-c4 cells with bacterial 
ligands. We also stimulated cells (passage 32-42) for 3 hours and 24 hours using ligands 
of cytoplasmic and endosomal PRRs. γ-D-Glu-mDAP (iE-DAP: catalog number tlrl-dap) 
was used at10 µg/ml, muramyl dipeptide (MDP: catalog number tlrl-mdp) at 10 µg/ml, 
polyinosonic:polycytidylic acid (Poly I:C: catalog number tlrl-pic) at 5 µg/ml, Poly I:C 
complexed with lyovec (Poly I:C/lyovec: catalog number tlrl-piclv) at1 µg/ml, and 
Imiquimod (catalog number tlrl-imq) at 5 µg/ml. All PRRs ligands were bought from 
Invivogen, CA, USA.  
5.2.3 RNA extraction and cDNA preparation 
After 3 hours or 24 hours of incubation with ligands, cells were washed three 
times with 1X PBS. Cells were then trypsinized using 0.05% Trypsin-EDTA and 
centrifuged to form a pellet. RNA was extracted from pelleted cells using RNeasy Mini 
Kit (catalog number 74101, Qiagen, Valencia, CA, USA) and kit protocol. RNA was 
quantified using Thermo Scientific™ NanoDrop 2000. The RNA thus obtained was used 
to prepare cDNA. 1 µg of RNA was reverse transcribed to cDNA using TaqMan reverse 
transcription kit and kit protocol (TaqMan reverse transcription reagents, Applied 
Biosystems, catalog number N8080234).  
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5.2.4 RT-qPCR for quantifying gene expression 
For RT-qPCR 2 µl of diluted cDNA (1:5 dilution), 1 µl each of forward and 
reverse primer, 10 µl of RT² SYBR® Green/ROX qPCR mastermix (catalog number 
330501, Qiagen, Valencia, CA, USA) and 6 µl of nuclease free water was added. The 
thermal profile used for amplification was: 2 minutes at 500C; 10 minutes at 950C; 
followed by 40 cycles of 45 seconds (15 seconds for cytokine genes) at 950C, 30 seconds 
at 600C and 30 seconds at 720C. Ramping speed was set at 1.60C/second. QuantStudio™ 
6 Flex Real-Time PCR System (Applied Biosystems, NJ, USA) was used. Data were 
normalized using housekeeping gene hypoxanthine phosphoribosyl transferase 1 (Hprt-
1). Primer sequence previously used (138) for amplification of bovine TLR 1-9 gene, 
cytokine genes (138, 200)  and Hprt-1 as housekeeping gene (278) are listed in Table 7 
and 8. RT-qPCR was used to identify any changes in TLRs, pro-inflammatory and anti-
inflammatory cytokines, after stimulation with PRR ligands.  
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Table 7: Primer sequence of genes along with gene bank accession number used in 
analysis of TLRs expression of BIEC-c4 cells 
 
 
Forward primer Reverse primer Accession 
number 
TLR 1 CAT TCC TAG CAG CTA 
CCA CAA GCT 
TGG GCC ATT CCA AAT 
AAG TTC T 
NM_001046
504 
TLR 2 GGG TGC TGT GTC ACC 
GTT TC 
GCC ACG CCC ACA TCA 
TCT 
NM_174197 
TLR 3 GGG CAC CTG GAG GTC 
CTT 
TTC CTG GCC TGT GAG 
TTC TTG 
NM_001008
664 
TLR 4 AGC ACC TAT GAT GCC 
TTT GTC A 
GTT CAT TCC GCA CCC 
AGT CT 
NM_174198 
TLR 5 GTC CCC AAC ACC ACC 
AAG AG 
GCG GTT GTG ACT GTC 
CTG ATA TAG 
NM_001040
501 
TLR 6 TTT ACC CTC AAC CAC 
GTG GAA 
GGG CCA AAG GAA CTG 
AAA AAC 
NM_001001
159 
TLR 7 CAC CAA CCT TAC CCT 
CAC CAT T 
GTC CAG CCG GTG AAA 
GGA 
NM_001033
761 
TLR 8 TGT GTT TAG AGG AAA 
GGG ATT GG 
TCT GCA TGA GGT TGT 
CGA TGA 
NM_001033
937 
TLR 9 CAG TGG CCA GGG 
TAG TTT CTG 
CCG GTT ATA GAA GTG 
ACG GTT GT 
NM_183081 
Hprt-1 GGATTACATCAAAGCA
CTGAACA 
CATTGTCTTCCCAGTGTCA
ATT 
NM_001034
035 
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Table 8: Primer sequence of genes along with gene bank accession number used in 
analysis of cytokines expression of BIEC-c4 cells 
 
 
Forward primer Reverse primer Accession 
number 
IL-1α CAG TTG CCC ATC CAA 
AGT TGT T 
TGC CAT GTG CAC CAA 
TTT TT 
NM_174092 
IL-1β GAG CCT GTC ATC TTC 
GAA ACG 
GCA CGG GTG CGT CAC A NM_174093 
TNF-α CGC ATT GCA GTC TCC 
TAC CA 
GGG CTC TTG ATG GCA 
GAC A 
NM_173966 
IL-6 CCA CCC CAG GCA GAC 
TAC TTC 
CCA TGC GCT TAA TGA 
GAG CTT 
NM_173923 
IL-8 TGC TCT CTT GGC AGC 
TTT CC 
TCT TGA CAG AAC TGC 
AGC TTC AC 
NM_173925 
IL-10 AAGGTGAAGAGAGTCT
TCAGTGAGC 
TGCATCTTCGTTGTCATGT
AGG 
NM_174088 
 
 
5.2.5 Statistical analysis for interpretation of RT-qPCR data 
To compare the change in TLR expression after ligand stimulation, double delta 
Ct (ΔΔCt) was calculated using the method previously described (201). Change in 
mRNA gene expression was calculated as 2-ΔΔCt. The method uses the following 
equation to calculate ΔΔCt: 
ΔΔCt=∆Ct Treatment (Ct of reference gene Treatment-Ct Housekeeping gene 
Treatment)- ∆Ct Control (Ct of reference gene Control-Ct Housekeeping gene Control). 
A two tailed Student’s t-test was then used to compare fold expression changes 
after treatment with ligands. A p-value of less than 0.05 (p<0.05) was considered 
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significant. GraphPad prism 7.04 was used to prepare graphs. Data are expressed as a 
mean ± standard error of the mean.  
5.3 Results 
5.3.1 Responses of BIEC-c4 cells at 3-hour and 24-hour after stimulation with 
bacterial ligands of surface expressed PRRs  
Three hours stimulation of BIEC-c4 cell with bacterial ligands LPS, PGN and 
FLA resulted in no significant changes in TLRs genes expressions (Figure 29-31). At 24-
hour, PGN significantly upregulated TLR 3 (1.73±0.14, p=0.04), and TLR 9 (1.41±0.07, 
p=0.03) gene expression (Figure 30). LPS significantly upregulated cytokines IL-10 
(2.42±0.2, p=0.02), and IL-8 (9.78±1.83, p=0.04) gene expression after 3-hour 
stimulation. At 24 hour, LPS also significantly upregulated IL-6 (3.58±0.15, p=0.00), and 
IL-8 (12.99±2.06, p=0.03) (Figure 32). PGN stimulation did not induce any significant 
changes in any cytokine gene expression at both 3 hours and 24 hour time points. FLA at 
3-hour downregulated IL-1β (0.31±0.1, p=0.02) (Figure 34) gene expression. 
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Fig 29: Fold changes in TLRs genes expressions in BIEC-c4 cells upon stimulation with 
LPS. Data are expressed as a mean of 3 independent experiments and error bar represents 
standard error of the mean. A significant difference in gene expression after LPS 
treatment is denoted by an asterisk (*=p<0.05, **=p≤0.01). 
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Fig 30: Fold changes in TLRs genes expressions in BIEC-c4 cells upon stimulation with 
PGN. Data are expressed as a mean of 3 independent experiments and error bar 
represents standard error of the mean. A significant difference in gene expression after 
PGN treatment is denoted by an asterisk (*=p<0.05, **=p≤0.01). 
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Fig 31: Fold changes in TLRs genes expressions in BIEC-c4 cells upon stimulation with 
FLA. Data are expressed as a mean of 3 independent experiments and error bar represents 
standard error of the mean. A significant difference in gene expression after FLA 
treatment is denoted by an asterisk (*=p<0.05, **=p≤0.01). 
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Fig 32: Fold changes in cytokines genes expressions in BIEC-c4 cells upon stimulation 
with LPS. Data are expressed as a mean of 3 independent experiments and error bar 
represents standard error of the mean. A significant difference in gene expression after 
LPS treatment is denoted by an asterisk (*=p<0.05, **=p≤0.01). 
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Fig 33: Fold changes in cytokines genes expressions in BIEC-c4 cells upon stimulation 
with PGN. Data are expressed as a mean of 3 independent experiments and error bar 
represents standard error of the mean. A significant difference in gene expression after 
PGN treatment is denoted by an asterisk (*=p<0.05, **=p≤0.01). 
112 
 
 
 
C
o
n
tr
o
l
IL
-1
 b
e
ta
T
N
F
-a
lp
h
a
IL
-6
IL
-8
IL
-1
0
0
1
2
3
4
5
5
10
15
20
25
30
Cytokines
F
o
ld
 c
h
a
n
g
e
s
 i
n
 m
R
N
A
FLA (3 hour)
FLA (24 hour)
*
 
Fig 34: Fold changes in cytokines genes expressions in BIEC-c4 cells upon stimulation 
with FLA. Data are expressed as a mean of 3 independent experiments and error bar 
represents standard error of the mean. A significant difference in gene expression after 
FLA treatment is denoted by an asterisk (*=p<0.05, **=p≤0.01). 
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5.3.2 The responses of BIEC-c4 cells at 3-hour and 24-hour after stimulation with 
ligands of cytoplasmic and endosomal PRRs  
Out of various ligands of cytoplasmic and endosomal PRRs, only iE-DAP, MDP, 
and poly (I:C) altered the expression of TLRs in BIEC-c4 cells. iE-DAP stimulation at 3 
hours significantly upregulated the expression of TLR 9 gene but expression of none of 
the other TLRs was affected (Figure 35). MDP after 24-hour stimulation upregulated 
TLR 9 (2.13±0.14, p=0.01) (Figure 36). Poly (I:C) after 3-hour stimulation upregulated 
TLR 8 (3.9±0.54, p=0.03), and TLR 9 (7.41±1.0, p=0.02) (Figure 37) gene expression. In 
general, we observed no alteration in TLRs expressions after 24 hours of stimulation with 
any ligands of cytoplasmic and endosomal PRRs except MDP (Figure 35-39).  
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Fig 35: Fold changes in TLRs genes expressions in BIEC-c4 cells upon stimulation with 
iE-DAP. Data are expressed as a mean of 3 independent experiments and error bar 
represents standard error of the mean. A significant difference in gene expression after 
iE-DAP treatment is denoted by an asterisk (*=p<0.05, **=p≤0.01). 
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Fig 36: Fold changes in TLRs genes expressions in BIEC-c4 cells upon stimulation with 
MDP. Data are expressed as a mean of 3 independent experiments and error bar 
represents standard error of the mean. A significant difference in gene expression after 
MDP treatment is denoted by an asterisk (*=p<0.05, **=p≤0.01). 
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Fig 37: Fold changes in TLRs genes expressions in BIEC-c4 cells upon stimulation with 
Poly (I:C). Data are expressed as a mean of 3 independent experiments and error bar 
represents standard error of the mean. A significant difference in gene expression after 
Poly (I:C) treatment is denoted by an asterisk (*=p<0.05, **=p≤0.01). 
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Fig 38: Fold changes in TLRs genes expressions in BIEC-c4 cells upon stimulation with 
Poly (I:C)/Lyovec. Data are expressed as a mean of 3 independent experiments and error 
bar represents standard error of the mean. A significant difference in gene expression 
after Poly (I:C)/Lyovec treatment is denoted by an asterisk (*=p<0.05, **=p≤0.01) 
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Fig 39: Fold changes in TLRs genes expressions in BIEC-c4 cells upon stimulation with 
imiquimod. Data are expressed as a mean of 3 independent experiments and error bar 
represents standard error of the mean. A significant difference in gene expression after 
imiquimod treatment is denoted by an asterisk (*=p<0.05, **=p≤0.01). 
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5.4 Discussion 
Host-specific in-vitro system that expresses PRRs and responds to PAMPs is 
essential for studying disease pathogenesis and host immune responses against 
pathogens. In this study, BIEC-c4 cells expressed various TLRs and responded to various 
bacterial associated ligands of PRRs by changing the expression of TLRs, pro-
inflammatory and anti-inflammatory cytokines.  
The intestinal epithelium is constantly exposed to the gut microbiota. There is a 
dynamic interaction between intestinal mucosa and gut microbes.  Investigating these 
interactions is essential for better understanding of inflammatory and enteric diseases 
where this delicate interaction is perturbed (279). Intestinal epithelium should 
expediently detect pathogens from commensals and mount an effective immune response. 
PRRs especially TLRs, NLRs, RLRs recognize molecular patterns conserved across the 
pathogens. Pathogen sensing by PRRs results in activation of transcription factors and 
ultimately release of cytokines, chemokines and growth factors (280). Cytokines and 
chemokines released in intestinal lumen are key players in regulating barrier integrity 
(195, 204). Understanding cell specific responses and intracellular mechanisms that 
generate innate immune responses against enteric pathogens are crucial for the 
development of control methods against such pathogens (126). 
In this study, we first analyzed putative TLRs 1-9 expression in BIEC-c4 cells. To 
identify if these cells respond to various pathogen associated molecular patterns (PAMPs) 
and initiate any downstream signaling, we stimulated cells for either 3 hours or 24 hours 
with various ligands of PRRs. Stimulation for 3 hours mimicked early innate immune 
responses while 24 hours point mimicked late innate immune responses. LPS did not alter 
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expression of various TLRs genes at 3-hour or 24-hour stimulation. However, we 
observed upregulation of IL-8 and IL-10 genes at 3 hours and IL-6 and IL-8 at 24-hour 
after LPS stimulation. LPS from gram negative bacteria is a potent immunostimulatory 
structure. LPS consists of endotoxin Lipid A, core oligosaccharide, and O-antigen. Lipid 
A is recognized by TLR 4 (205, 206). LPS recognition by TLR 4 requires accessory 
molecules. LPS binding protein binds to LPS allowing the association between LPS and 
co-receptor CD14 (monocyte differentiating antigen). CD14 facilitates the binding of 
LPS to TLR 4/MD-2 complex (207, 208). Recognition of LPS by TLR 4 leads to signal 
transduction either by MyD88 (209) or by TRIF pathway (210) ultimately leading to 
activation of transcription factors like NF-κB, AP-1, and IRF-3. Activation of 
transcription factors results in expression of pro-inflammatory cytokines like IL-6, IL-8, 
TNF-α, and Type -I IFN (20, 211). Previous studies have shown that stimulation of 
bovine intestinal epithelial cells by E. coli PAMPs resulted in increased expression of 
pro-inflammatory cytokines like IL-6, IL-8, IL-1α, IL-1β (138, 265). Continued 
activation of TLR 4 can lead to inflammation induced damages and thus negative 
regulation needs to be in place. Radioprotective protein 105 (RP105), single 
immunoglobulin IL-1R-related molecule, and IL1-RL1 protein negatively regulate TLR 4 
signaling. LPS challenged mice that are deficient for RP105 showed elevated levels of 
TNF-α in serum (213). After TLR signaling, the LPS-TLR4-MD2 complex is 
endocytosed in endosome or lysosomes where degradation of TLR 4 occurs (214). This 
degradation can result in the termination of TLR 4 induced production of TNF (215).  
Peptidoglycan (PGN) is a major constituent of gram positive bacteria and is 
composed of N-acetlyglucosamine (GlcNac) and N-acetylmuramic acid (MurNac) linked 
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by β-(1-4) linkage (49). PGN’s role in producing an inflammatory response and 
stimulating immune response has been long known (50, 51). TLR 2 knocked out mice 
revealed that TLR 2 is involved in recognition of PGN (216). In various cell models, 
PGN induces production of pro-inflammatory cytokines like IL-6, IL-1α/β, TNF-α (217). 
In this study, TLR 3 and TLR 9 genes expressions were significantly upregulated at 24 
hours after PGN stimulation although no changes in cytokine expression were observed. 
PGN stimulation did not alter TLR 2 expression at 3-hour or 24-hour time points and 
showed no significant changes in cytokine expression. In other in-vitro models, cells 
responded to PGN treatment by altering the expression of TLRs other than TLR 2 (219). 
TLR 1 and TLR 6 are functionally co-related with TLR 2 in recognizing different classes 
of lipopeptides (220). Most of the studies co-relating PGN to TLR 2 used commercially 
obtained PGN from Staphylococcus aureus. This preparation is often co-purified with 
other cell wall components and pure PGN has failed to respond to TLR 2 in many 
experiments (221). The authors (221) even claimed that PGN sensing did not occur via 
TLR 2 which was later refuted (222).   
Flagellin (FLA), a subunit of flagellum protein, provides motility to the 
bacterium. Initially considered as a virulence factor, subsequent in-vitro studies 
demonstrated its pro-inflammatory role (223, 224). Later it was demonstrated that 
recognition of flagellin by TLR 5 induced production of pro-inflammatory cytokines like 
TNF-α, IL-1β (225). In this study, 3-hour and 24-hourstimulation of BIEC-c4 cells with 
flagellin did not alter expression of any TLRs but downregulated IL-1β at 3-hour time 
point. Recent studies have shown cross talk among various PRRs and that specific PRR 
ligand can overexpress or inhibit expression of other PRRs. Among multiple ligands, LPS 
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showed a more pronounced effect on modulating expression of other PRRs, and PAMPs 
other than LPS downregulated the expression of TLR 4 (226). Triggering of single TLR 
when the specific ligand is recognized is insufficient to mount an effective innate 
immune response and thus triggering of other PRR family or multiple TLRs may be 
required to mount a strong immune response. Often the synergism exists between PRRs 
that mediate effector response through different signaling pathways (43, 227).   
Nucleotide-binding oligomerization domain (NOD) proteins are cytoplasmic 
proteins involved in recognition of intracellular bacteria. NOD proteins have N-terminal 
caspase recruitment domain (CARD), leucine rich repeats in C-terminus and nucleotide 
binding domain in between. NOD-1 and NOD-2 are two NOD proteins that recognize 
two different peptidoglycan fragments and are involved in pathogen recognition (48). 
NOD-1/CARD4 recognizes peptidoglycan GlcNac-MurNac-L-Ala-γ-D-Glu-meso-DAP 
(GM-TriDAP/iE-DAP) whereas NOD-2 recognizes muramyl dipeptide, MurNac-L-
AlaD-isoGln. NOD-1 and NOD-2 activate NF-κB by recruitment of receptor-interacting 
protein (RIP) 2 leading to secretion of pro-inflammatory cytokines while type I 
interferons are secreted when IRF3/IRF7 dependent pathway is activated by these 
receptors (52-56). In this study, iE-DAP upregulated expression of TLR 9 gene 
expression at 24 hours after stimulation in BIEC-c4 cells while MDP upregulated TLR 9 
gene after 3-hour stimulation. MDP alone has been shown to evoke weak immune 
stimulation (47, 228-231). Addition of TLR agonists like LPS, lipoteichoic acid along 
with MDP has been shown to evoke a strong immune response (232, 233). TLR 
stimulation may promote internalization of MDP and iE-DAP which facilitates 
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recognition by NOD proteins. NOD proteins also interact with other intracellular 
molecules that positively or negatively regulate NOD signaling pathways (47).  
During viral replication, most of the viruses produce double stranded RNA 
(dsRNA) as replication intermediate. This dsRNA is sensed by PRRs present in the 
cytosol, and endosomes. TLR 3 is membrane receptor usually present in endosomes and 
recognizes dsRNA. Retinoic acid-inducible gene I (RIG-I), melanoma differentiation-
associated gene -5 (MDA-5), and NLR pyrin domain 3 (Nlrp3) are present in the cytosol 
and associated with sensing of dsRNA (62, 234-237). Recognition of dsRNA by these 
receptors results in the production of type -I interferon (IFN) (238, 239). TLR 3 uses 
MyD88 independent pathway and uses toll/interleukin-1 receptor (TIR) domain-
containing adaptor inducing IFN-β (TRIF) ultimately leading to induction of IFN-β (210, 
240, 241). Poly (I:C) is the synthetic analog of dsRNA and is used to mimic viral 
infection in experimental conditions (242, 243). Recent reports have shown possible role 
of CD14 in internalizing extracellular dsRNA or poly (I:C) and delivering it to TLR 3 
located in the endosomal and lysosomal membrane (244). Apart from IFN, IL-6 induced 
from TLR 3 expression is reported to have a detrimental effect during infection with 
single stranded RNA viruses (245-247). Apart from IFN production, NF-κB activation 
also induces secretion of IL-32. IL-32 induces production of pro-inflammatory cytokines 
like IL-6, IL-8, TNF-α, IL-1β (241, 248). In BIEC-c4 cells, we observed upregulation of 
TLR 8 and TLR 9 at 3-hour stimulation with poly (I:C). However, we did not observe 
any significant changes in TLR 3 expression.  
Poly (I:C) complexed with transfecting reagent lyovec did not induce any 
significant changes in TLRs expressions in BIEC-c4 cells. Accumulation of intracellular 
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dsRNA during viral replication and subsequent induction of IFN production by the host 
cell is different from the IFN produced by sensing of extracellular dsRNA (249). 
Intracellular dsRNA is sensed by RIG-I, MDA-5. RIG-I and MDA-5 belong to RIG-I like 
receptor (RLR) family. RIG-I senses blunt ended 5’phosphorylated dsRNA whereas 
MDA-5 recognizes long (>1000 nucleotide) dsRNA (58-60) Both RIG-I and MDA-5 are 
RNA helicases that have caspase recruitment domain (CARD) and helicase domain. 
Signal transduction after sensing of intracellular dsRNA is through CARD in both RIG-I 
and MDA-5. This results in activation of IRF-3 and NF-κB and subsequent production of 
IFNs (type I, and type III) and as well as pro-inflammatory cytokines like IL-6 and IL-8 
(61-64).  
Imiquimod is a synthetic guanosine analog with antiviral and anti-tumor activity 
(250). Imiquimod is an immune response modifier that specifically activates TLR 7 
signaling pathway (251). Through MyD88 signaling cascade imiquimod induces 
activation of transcription factors like NF-κB, and MAPKs (mitogen activated protein 
kinases). Activation of these transcription factors lead to the induction of IFN-α, IL-12, 
TNF-α, IL-6 and other cytokines (250, 252-255). In this study, BIEC-c4 cells did not 
respond to imiquimod stimulation although they have been shown to express TLR 7 gene. 
Immune cells like phagocytes produce reactive oxygen species (ROS) during the 
microbial invasion. These ROS are highly reactive and induce oxidative damage to 
nucleic acids, lipids, and proteins. The Guanosine and cytosine are more prone to 
undergo oxidative damage due to their electronic configuration. The damaged guanosine 
may be sensed by TLR 7 and TLR 8 and produce necessary cytokines for activating 
immune cells (251, 256). 
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In this study, we studied the putative expression of TLRs by BIEC-c4 cells. There 
are limited number of studies on the expression of PRRs by the bovine ileal epithelial cell 
line. To the author's knowledge, no studies on the role of the bovine ileal epithelial cell 
line in innate immunity have been carried out. This study also analyzed the response of 
bovine ISEMFs to various PAMPs and associated cytokine expression but did not 
analyze expression of NLRs and RLRs genes. This study only analyzed changes in gene 
expression in response to various PAMPs. This study is limited in that it did not analyze 
whether alteration in mRNA expression was being carried out to protein level. No 
experiment to quantify cytokine levels in cell culture supernatant was performed and 
changes in IFN gene in response to viral PAMPs was not analyzed.  Despite these 
limitations, we demonstrated that bovine BIECs express TLRs 1-9 and respond to various 
bacterial PAMPs. These cells failed to respond to ligands of many cytoplasmic and 
endosomal PRRs. These cloned epithelial cells were homogenous in distribution and thus 
are not a true representative of tissue environment. These BIEC-c4 cells did not polarize, 
were spontaneously immortalized and did not allow replication of bovine rotavirus, 
bovine coronavirus and bovine viral diarrhea virus (unpublished data). We concluded that 
these are immature or undifferentiated epithelial cells. The BIEC-c4 clone could have 
arisen from intestinal stem cells and thus did not respond properly to ligands of 
cytoplasmic and endosomal PRRs. These cells were established from the 2-day old calf. 
Recent studies have shown that insufficient colonization by gut microbiota can lead to the 
defective immune system. Sufficient colonization by gut microbiota is essential for a 
fully functional immune system (281).  
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5.5 Conclusion 
Based on this study we conclude that BIEC-c4 cells express TLRs 1-9 and 
respond to many bacterial PAMPs. Thus, these cell line can be used to accumulate 
knowledge of signal transduction in response to various bacterial PAMPs such as LPS, 
PGN and FLA. However, BIEC-c4 cell line did not respond to viral PAMPs. 
Differentiating these cells into more mature epithelial cells and analyzing their responses 
to ligands of cytoplasmic and endosomal PRRs can help decide their relevance as an in-
vitro model. However, these cell line can be a good in-vitro model to study enteric 
bacterial pathogens. 
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Chapter 6: Conclusions and future directions 
We successfully developed primary ileal myofibroblast cultures from the 2-day 
old bovine calf. These ileal intestinal sub-epithelial myofibroblasts (ISEMFs) showed 
phenotypic characteristics typical of myofibroblasts. On immunocytochemistry ISEMFs 
demonstrated the presence of α-smooth muscle actin and vimentin. But absence of 
cytokeratin which confirmed the presence of pure myofibroblast cells. Since primary 
cells can be grown for finite passages, we immortalized primary ileal ISEMFs using 
SV40 large T antigen. Glycobiology of primary ISEMF cells and immortalized ISEMFs 
showed differences for some lectins. TLR expression analysis showed no differences 
between primary and immortalized ISEMFs.  
Earlier we had established primary bovine ileal epithelial cells (BIEC-c4) in our 
lab. Both primary ISEMFs and primary BIEC-c4 cells were from same calf and same 
ileal segment. In this study, we analyzed if both BIEC-c4 and ISEMF cells respond to 
various PAMPs. On analysis, both BIEC-c4 and ISEMF responded to bacterial PAMPs 
while only ISEMF mainly responded to ligands of cytoplasmic and endosomal PRRs.  
Based on our finding we concluded that bovine ISEMFs can be a good model to 
study innate immune responses occurring at sub-epithelial compartment. Primary ISEMF 
cells can also be used to study PRRs signaling pathways. ISEMF cells have emerged as a 
mediator of diverse functions. ISEMFs are involved in wound healing, regulation of 
barrier function of the intestinal epithelium, differentiation and maturation of epithelium 
and in generating innate immune responses occurring at sub-epithelial compartment. 
ISEMF cells developed and characterized in our lab can be a good model to study 
intestinal inflammatory disease pathogenesis as well. 
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BIEC-c4 cells responded only to bacterial PAMPs. BIEC-c4 cells established in 
our lab was a cloned cell line. BIEC-c4 cells behaved like stem cells as they did not 
polarize on culture and kept growing for more than 100 passages without 
immortalization.  Since they responded to bacterial PAMPs, we concluded that these cells 
can be used to study enteric bacterial disease pathogenesis.  
Since our findings were based on RT-qPCR assay, further studies to corroborate 
these findings at protein levels are essential. Western blot to detect changes in TLR 
proteins upon stimulation with PAMPs can bolster the findings. Cytokine ELISA of cell 
supernatants after stimulation with PAMPs can further support our data. Bacterial 
invasion assay on this BIEC-c4 cells and subsequent analysis of TLRs expression could 
mimic in-vivo conditions. Transforming immature BIEC-c4 cells to more mature and 
differentiated epithelial cells expressing tight junction proteins should be carried out. A 
2D co-culture of primary ISEMF and BIEC-c4 cells to investigate ISEMFs role in 
maturation and differentiation of intestinal epithelial could be next project using these 
cells.  
Overstimulation of TLRs often leads to excessive cytokine production which can 
be detrimental to host. A detailed understanding of key signaling molecules involved in 
TLR signaling in these cells as a model can be beneficial in developing therapeutic 
strategies of various infectious diseases.  
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